Compositions and methods for regulating cell signaling with chimeric receptors

Chimeric signaling receptors with specific polypeptide configurations allow controlled cell signaling in target cells, addressing the challenge of off-target effects and enabling treatment of inflammatory and autoimmune diseases through precise regulation of IL signaling pathways.

JP2024541588APending Publication Date: 2024-11-08GENTIBIO INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024532194
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-29
Filing Date
2022-11-29
Publication Date
2024-11-08

Smart Images

  • Figure 2024541588000001_ABST
    Figure 2024541588000001_ABST
Patent Text Reader

Abstract

Described herein are compositions and methods for generating regulatory T cells (Tregs) with a stable phenotype by modifying cells to activate specific interleukin pathways.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Reference to Electronic Sequence Listing The contents of the electronic sequence listing (G097170022WO00-SEQ-JXV.xml; size: 30,388 bytes; creation date: November 29, 2022) are incorporated herein by reference in their entirety. [Background technology]

[0002] Initiating or maintaining cell signaling to achieve a particular cellular function serves many therapeutic purposes, for example, to initiate or maintain a particular cellular function or phenotype in a therapeutic cell. Summary of the Invention

[0003] The present disclosure provides, in some embodiments, a chimeric signaling receptor for controlling ST2 signaling in a cell, the chimeric signaling receptor comprising a first polypeptide and a second polypeptide, the first polypeptide comprising a first extracellular domain, a first transmembrane domain, and a first membrane proximal signaling domain, the second polypeptide comprising a second extracellular domain, a second transmembrane domain, and a second membrane proximal signaling domain, the first extracellular domain comprising a rapamycin binding domain of FK binding protein 12 (FKBP) or a functional fragment thereof, and the second extracellular domain comprising , the rapamycin binding domain of FKBP12-the rapamycin binding domain of mTOR (FRB) or a functional fragment thereof, and (i) the first membrane proximal signaling domain comprises the intracellular signaling domain or a functional fragment of ST2 and the second membrane proximal signaling domain comprises the intracellular signaling domain or a functional fragment of IL1RAP, or (ii) the first membrane proximal signaling domain comprises the intracellular signaling domain or a functional fragment of IL1RAP and the second membrane proximal signaling domain comprises the intracellular signaling domain or a functional fragment of ST2.

[0004] The present disclosure provides, in some embodiments, a chimeric signaling receptor for controlling IL18R signaling in a cell, the chimeric signaling receptor comprising a first polypeptide and a second polypeptide, the first polypeptide comprising a first extracellular domain, a first transmembrane domain, and a first membrane proximal signaling domain, the second polypeptide comprising a second extracellular domain, a second transmembrane domain, and a second membrane proximal signaling domain, the first extracellular domain comprising a rapamycin binding domain of FK binding protein 12 (FKBP) or a functional fragment thereof, and the second extracellular domain comprising a rapamycin binding domain of FKBP or a functional fragment thereof. The rapamycin binding domain of P12-rapamycin binding domain (FRB) of mTOR or a functional fragment thereof, and (i) the first membrane proximal signaling domain comprises the intracellular signaling domain or a functional fragment of IL18R1 and the second membrane proximal signaling domain comprises the intracellular signaling domain or a functional fragment of IL18RAP, or (ii) the first membrane proximal signaling domain comprises the intracellular signaling domain or a functional fragment of IL18RAP and the second membrane proximal signaling domain comprises the intracellular signaling domain or a functional fragment of IL18R1.

[0005] The present disclosure provides, in some embodiments, a chimeric signaling receptor for controlling IL36R signaling in a cell, the chimeric signaling receptor comprising a first polypeptide and a second polypeptide, the first polypeptide comprising a first extracellular domain, a first transmembrane domain, and a first membrane proximal signaling domain, the second polypeptide comprising a second extracellular domain, a second transmembrane domain, and a second membrane proximal signaling domain, the first extracellular domain comprising a rapamycin binding domain of FK binding protein 12 (FKBP) or a functional fragment thereof, and the second extracellular domain comprising a rapamycin binding domain of FK binding protein 12 (FKBP) or a functional fragment thereof. The first membrane proximal signaling domain comprises the rapamycin binding domain of FKBP12-rapamycin binding domain of mTOR (FRB) or a functional fragment thereof, and (i) the first membrane proximal signaling domain comprises the intracellular signaling domain or a functional fragment of IL36R and the second membrane proximal signaling domain comprises the intracellular signaling domain or a functional fragment of IL1RAP, or (ii) the first membrane proximal signaling domain comprises the intracellular signaling domain or a functional fragment of IL1RAP and the second membrane proximal signaling domain comprises the intracellular signaling domain or a functional fragment of IL36R.

[0006] The present disclosure provides, in some embodiments, a chimeric signaling receptor for controlling IL10R signaling in a cell, the chimeric signaling receptor comprising a first polypeptide and a second polypeptide, the first polypeptide comprising a first extracellular domain, a first transmembrane domain, and a first membrane proximal signaling domain, the second polypeptide comprising a second extracellular domain, a second transmembrane domain, and a second membrane proximal signaling domain, the first extracellular domain comprising a rapamycin binding domain of FK binding protein 12 (FKBP) or a functional fragment thereof, and the second extracellular domain comprising a rapamycin binding domain of FK binding protein 12 (FKBP) or a functional fragment thereof. The first membrane proximal signaling domain comprises the rapamycin binding domain of KBP12-the rapamycin binding domain (FRB) of mTOR or a functional fragment thereof, and (i) the first membrane proximal signaling domain comprises the intracellular signaling domain or a functional fragment of IL10R1 and the second membrane proximal signaling domain comprises the intracellular signaling domain or a functional fragment of IL10R2, or (ii) the first membrane proximal signaling domain comprises the intracellular signaling domain or a functional fragment of IL10R2 and the second membrane proximal signaling domain comprises the intracellular signaling domain or a functional fragment of IL10R1.

[0007] The present disclosure provides, in some embodiments, a chimeric signaling receptor for controlling LIFR signaling in a cell, the chimeric signaling receptor comprising a first polypeptide and a second polypeptide, the first polypeptide comprising a first extracellular domain, a first transmembrane domain, and a first membrane proximal signaling domain, the second polypeptide comprising a second extracellular domain, a second transmembrane domain, and a second membrane proximal signaling domain, the first extracellular domain comprising a rapamycin binding domain of FK binding protein 12 (FKBP) or a functional fragment thereof, the second extracellular domain comprising a rapamycin binding domain of FKBP12-rapamycin binding domain (FRB) of mTOR or a functional fragment thereof, (i) the first membrane proximal signaling domain comprises an intracellular signaling domain or a functional fragment of gp130, and the second membrane proximal signaling domain comprises an intracellular signaling domain or a functional fragment of LIFrβ, or (ii) the first membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of LIFrβ, and the second membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of gp130.

[0008] The present disclosure provides, in some embodiments, a chimeric signaling receptor comprising a first polypeptide and a second polypeptide, wherein the first polypeptide comprises a first extracellular domain, a first transmembrane domain, a first membrane proximal signaling domain, and a first membrane distal signaling domain, and the second polypeptide comprises a second extracellular domain, a second transmembrane domain, a second membrane proximal signaling domain, and a second membrane distal signaling domain.

[0009] In some embodiments, the first membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of ST2, and the second membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL1RAP; The first membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of IL2Rγ, and the second membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of IL2Rβ.

[0010] In some embodiments, the chimeric signaling receptor further comprises an extracellular linker. In some aspects, the extracellular linker comprises a (G4S)xN peptide linker or an extracellular hinge of IL1RI, IL1RII, IL1RAP, IL2Rβ, IL2Rγ, IL10R1, IL10R2, IL18R1, IL18RAP, ST2, IL36R, LIFrβ, or gp130.

[0011] In some aspects, the present disclosure provides a chimeric signaling receptor comprising a first polypeptide and a second polypeptide, wherein the first polypeptide and the second polypeptide each comprise a sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to a sequence selected from SEQ ID NOs: 1-19.

[0012] In some embodiments, the first polypeptide and the second polypeptide are each identical to a sequence selected from SEQ ID NOs: 1-19. In some embodiments, the present disclosure provides a nucleic acid encoding the first polypeptide or the second polypeptide of a chimeric signaling receptor described herein. In some embodiments, the nucleic acid encodes the first polypeptide and the second polypeptide. In some embodiments, the nucleic acid further comprises a promoter operably linked to a coding sequence encoding the first polypeptide and / or the second polypeptide. In some embodiments, the promoter is a constitutive promoter. In some embodiments, the constitutive promoter is EF-1α, a PGK promoter, or an MND promoter. In some embodiments, the promoter is an MND promoter. In some embodiments, the promoter is an inducible promoter. In some embodiments, the inducible promoter is inducible by a drug or a steroid.

[0013] In some embodiments, the disclosure provides a vector comprising any one of the nucleic acids described herein. In some embodiments, the vector is a viral vector. In some embodiments, the vector is an adenovirus-associated viral (AAV) vector. In some embodiments, the AAV vector is derived from AAV of serotype AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, or AAV11. In some embodiments, the viral vector is a lentiviral vector. In some embodiments, the vector is a plasmid. In some embodiments, the vector is a bacterial artificial chromosome. In some embodiments, the vector is a human artificial chromosome.

[0014] In some embodiments, the present disclosure provides lipid nanoparticles comprising any one of the nucleic acids described herein or any one of the vectors described herein. In some embodiments, the disclosure provides a cell comprising any one of the chimeric signaling receptors described herein or any one of the nucleic acids described herein. In some embodiments, the cell is a stem cell or a T cell. In some embodiments, the cell is a CD3+, CD4+, or CD8+ T cell. In some embodiments, the cell is a Treg cell. In some embodiments, the cell is a FoxP3+ Treg cell. In some embodiments, the cell is CTLA-4+, LAG-3+, CD25+, CD39+, CD27+, CD70+, GITR+, Neuropilin-1+, Galectin-1+, and / or IL-2Rα+. In some embodiments, the cell promotes the expansion of Tregs. In some embodiments, the cell has an ST2 phenotype. In some embodiments, the cell has a Tr1 phenotype.

[0015] In some embodiments, the disclosure provides a pharmaceutical composition comprising any one of the cells described herein and rapamycin or a rapalog. In some embodiments, the disclosure provides a method comprising administering to a subject any one of the pharmaceutical compositions described herein, or any one of the cells described herein.

[0016] In some embodiments, the subject has or is at risk of developing an inflammatory disease, an autoimmune disease, an allergic disease, or a condition associated with solid organ transplantation. In some embodiments, the inflammatory disease is selected from pancreatic islet cell transplantation, asthma, hepatitis, traumatic brain injury, primary sclerosing cholangitis, primary biliary cholangitis, polymyositis, stroke, Still's disease, acute respiratory distress syndrome (ARDS), uveitis, inflammatory bowel disease (IBD), ulcerative colitis, graft versus host disease (GvHD), induced tolerance to transplantation, transplant rejection, or sepsis.

[0017] In some embodiments, the autoimmune disease is type 1 diabetes, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, rheumatoid arthritis, early onset rheumatoid arthritis, ankylosing spondylitis, immune-mediated abortion, immune-mediated recurrent abortion, dermatomyositis, psoriatic arthritis, Crohn's disease, inflammatory bowel disease (IBD), ulcerative colitis, bullous pemphigoid, pemphigus vulgaris, autoimmune hepatitis, psoriasis, Sjogren's syndrome, or celiac disease.

[0018] In some embodiments, the allergic disease is allergic asthma, steroid-resistant asthma, atopic dermatitis, celiac disease, pollen allergy, food allergy, drug hypersensitivity, or contact dermatitis.

[0019] In some embodiments, the condition associated with a solid organ transplant is graft-versus-host disease. In some embodiments, the cells are autologous to the subject, hi some embodiments, the cells are allogeneic cells.

[0020] In some embodiments, the disclosure provides a method of making a modified cell comprising introducing into a cell any one of the nucleic acids described herein. [Brief description of the drawings]

[0021] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure and may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein. It should be understood that the data shown in the drawings are not intended to limit the scope of the present disclosure in any way. [Figure 1A] 1 illustrates a chimeric signaling receptor comprising a first polypeptide and a second polypeptide, the first polypeptide comprising a first extracellular domain, a first transmembrane domain, and a first membrane proximal signaling domain, and the second polypeptide comprising a second extracellular domain, a second transmembrane domain, and a second membrane proximal signaling domain. [Figure 1B]1 shows a chimeric signaling receptor comprising a first polypeptide and a second polypeptide, the first polypeptide comprising a first extracellular domain, a first transmembrane domain, a first membrane proximal signaling domain, and a first membrane distal domain, and the second polypeptide comprising a second extracellular domain, a second transmembrane domain, a second membrane proximal signaling domain, and a second membrane distal signaling domain. A chimeric signaling receptor with two signaling domains in each polypeptide allows for the initiation and / or maintenance of two cell signaling pathways within a cell. [Diagram 2] Examples of chimeric signaling receptors with different configurations of signaling domains are shown. CISC = chemical-inducible signaling complex. [Figure 3-1] Exemplary polypeptides that form the chimeric ST2.2 signaling receptors depicted in Figure 2 are shown. Each polypeptide includes an extracellular domain containing an FRB or FKBP, a transmembrane domain ("TMD"), a membrane proximal signaling domain, a membrane distal linker, and a membrane distal signaling domain. [Figure 3-2] Same as above. [Figure 4A] 1 shows examples of chimeric signaling receptors with different configurations of signaling and transmembrane domains. [Figure 4B] 4A shows the results of a secreted embryonic alkaline phosphatase (SEAP) colorimetric assay demonstrating that murine CISC2 signals through the IL2:STAT5 signaling axis. Cells containing the various CISC receptors shown in FIG. 4A were stimulated with IL2 in the presence and absence of rapamycin. [Diagram 5] Exemplary polypeptides that can form chimeric RISE33 (RISE ST2) signaling receptors are shown in Figure 2. Each polypeptide includes an extracellular domain containing an FRB or FKBP, a transmembrane domain ("TMD"), a membrane proximal signaling domain, a membrane distal linker, and a membrane distal signaling domain. [Figure 6A]1 shows the results of a SEAP colorimetric assay demonstrating humanized CISC33 (RISE ST2) signaling through the IL33 signaling pathway. Cells were treated with the indicated doses of IL33 or rapamycin. [Figure 6B] 1 shows the results of a SEAP colorimetric assay demonstrating murine CISC33 (RISE ST2) signaling through the IL33 signaling pathway. Cells were treated with various doses of recombinant IL33 or rapamycin. [Figure 7] Examples of polypeptides that can form the chimeric RISE10 signaling receptors shown in Figure 2 are shown. Each polypeptide includes an extracellular domain containing an FRB or FKBP, a transmembrane domain ("TMD"), a membrane proximal signaling domain, a membrane distal linker, and a membrane distal signaling domain. [Figure 8] 1 shows an example of CISC signaling through the IL10 signaling pathway. Cells were treated with various doses of IL10 or rapamycin. [Figure 9A] 9A-9H show examples of amino acid sequences of CISC polypeptides. [Figure 9B] Same as above. [Figure 9C] Same as above. [Figure 9D] Same as above. [Figure 9E] Same as above. [Figure 9F] Same as above. [Figure 9G] Same as above. [Figure 9H] Same as above. [Figure 10] Exemplary flow cytometry results of T cells (HEK293, human CD4, and hEngTreg) transfected with RISE33 constructs are shown. [Figure 11-1] 1 shows exemplary flow cytometry results of CD4 T cells and Jurkat cells transfected with RISE33 (or mock transfected) and stimulated under different conditions. CD69 is a marker of T cell activation. [Figure 11-2] Same as above. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0022] Detailed Description It is difficult to initiate or maintain cell signaling to achieve a specific cell function or phenotype in a target cell without affecting other cells in vivo. This is at least because it is difficult to control the destination of a ligand that can be used to initiate or maintain cell signaling. For example, administration of a ligand to control cell signaling in a specific target cell may have a significant effect within the target, but may not have an extra-tissue or extra-cellular effect, which may be undesirable. The present disclosure provides a solution to overcome this difficulty when administering target cells (e.g., T cells, such as CAR-T cells) to a subject in whom cell signaling is to be controlled.

[0023] Provided herein are compositions and methods utilizing a chimeric signaling receptor expressed in a target cell for administration to a subject, where a specific cell signaling in the target cell is initiated or maintained by administering a ligand to the subject. The specific cell signaling is controlled by contacting a cell expressing the chimeric signaling receptor with a ligand that binds to the extracellular domain and activates the chimeric receptor. In some embodiments, binding of the ligand promotes dimerization of a first polypeptide of the chimeric receptor and a second polypeptide of the chimeric receptor via dimerization of a first extracellular domain of the first polypeptide and a second extracellular domain of the second polypeptide. A complex comprising a first polypeptide and a second polypeptide is referred to herein as a chemical-induced signaling complex (CISC), and in some embodiments as a rapamycin-induced signal enhancement (RISE) complex. The specific cell signaling that is controlled is controlled by the intracellular signaling domain of the chimeric receptor, and when activated by a ligand that binds to the extracellular domain of the receptor, the specific cell signaling is triggered. The particular cell signaling can be signaling involved in any cell function, such as proliferation, cell division and replication, DNA replication, protein synthesis, cytokine production, maintenance of a cytotoxic phenotype (e.g., as observed in cytotoxic T cells), cell homing, maintenance of a regulatory phenotype (e.g., as observed in regulatory T cells), antigen recognition and activation, or tissue repair.

[0024] Chimeric signaling receptors In some aspects, provided herein is a chimeric signaling receptor comprising a first polypeptide and a second polypeptide, the first polypeptide comprising a first extracellular domain, a first transmembrane domain, and a first membrane proximal signaling domain, and the second polypeptide comprising a second extracellular domain, a second transmembrane domain, and a second membrane proximal signaling domain, such that the first and second extracellular binding domains are capable of binding a ligand (e.g., a small molecule such as rapamycin or an analog thereof). A non-limiting schematic of this receptor is shown in Figure 1A.

[0025] In some embodiments, the first polypeptide of the chimeric signaling receptor further comprises a first membrane distal signaling domain and the second polypeptide of the chimeric signaling receptor further comprises a second distal signaling domain, a non-limiting schematic of which is shown in Figure IB.

[0026] FIG. 2 shows examples of chimeric signaling receptors provided herein that are activatable by rapamycin or a rapalog, and are described in more detail below. In some embodiments, the chimeric signaling receptor polypeptide (e.g., the first polypeptide or the second polypeptide) further comprises an extracellular linker between the extracellular domain and the transmembrane domain. In some embodiments, the chimeric signaling receptor polypeptide (e.g., the first polypeptide or the second polypeptide) further comprises a membrane proximal linker between the transmembrane domain and the membrane proximal signaling domain. In some embodiments, the chimeric signaling receptor polypeptide (e.g., the first polypeptide or the second polypeptide) further comprises a membrane distal linker between the membrane proximal signaling domain and the membrane distal signaling domain. In some embodiments, the chimeric signaling receptor provided herein comprises multiple linkers. In some embodiments, the chimeric signaling receptor polypeptide further comprises a signal peptide.

[0027] In some embodiments, the first extracellular domain and the second extracellular domain are dimerization domains that dimerize in the presence of a ligand. In some embodiments, the first extracellular domain is the same as the second extracellular domain, and the first and second extracellular domains homodimerize upon binding to a ligand. In some embodiments, the first extracellular domain is different from the second extracellular domain, and the first and second extracellular domains heterodimerize upon binding to a ligand. The ligand can be a small molecule, peptide, protein, or other biological entity (e.g., one that contains base pairs). In some embodiments, the ligand that activates the chimeric signaling receptor described herein is rapamycin or a rapalog. Rapamycin, a macrocyclic triene compound, is also known as sirolimus and is commercially available (e.g., RAPAMUNE®). In some embodiments, the ligand that activates the chimeric signaling receptor is wild-type rapamycin (e.g., a commercially available rapamycin such as RAPAMUNE®). In some embodiments, the ligand that activates the chimeric signaling receptor comprises a rapamycin having one, two, three, four, five, or more modifications relative to wild-type rapamycin. For example, in some embodiments, the methyl side chain of the rapamycin may be modified (e.g., extended). In some embodiments, the rapalog is everolimus, CCI-779, C20-methallylrapamycin, C16-(S)-3-methylindolerapamycin, C16-iRap, C16-(S)-7-methylindolerapamycin, AP21967, C16-(S)-butylsulfonamidorapamycin, AP23050, mycophenolate sodium, benidipine hydrochloride, AP1903, AP23573, or a metabolite or derivative thereof.

[0028] In some embodiments, the first extracellular domain comprises the rapamycin binding domain of FK binding protein 12 (FKBP) and the second extracellular domain comprises the rapamycin binding domain of FKBP12-rapamycin binding domain of mTOR (FRB). In some embodiments, the sequence of the FKBP domain is: GVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLE (SEQ ID NO: 23). In some embodiments, the FKBP domain can comprise a polypeptide having at least 50% identity (e.g., at least 50, at least 60, at least 70, at least 80, at least 90, at least 95, at least 98, at least 99, or at least 99.5% identity) to SEQ ID NO: 23. In some embodiments, the FKBP domain comprises up to 20 amino acid substitutions, up to 15 amino acid sequence substitutions, up to 10 amino acid substitutions. In some embodiments, the FKBP domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more amino acid sequence substitutions.

[0029] In some embodiments, the sequence of the FRB domain is EMWHEGLEEASRLYFGERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFRRISK (SEQ ID NO: 24). In some embodiments, the FRB domain can comprise a polypeptide having at least 50% identity (e.g., at least 50, at least 60, at least 70, at least 80, at least 90, at least 95, at least 98, at least 99, or at least 99.5% identity) to SEQ ID NO: 24. In some embodiments, the FRB domain comprises up to 20 amino acid substitutions, up to 15 amino acid sequence substitutions, up to 10 amino acid substitutions. In some embodiments, the FRB domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more amino acid sequence substitutions.

[0030] In one embodiment, the FRB domain comprises a T74L mutation. In some embodiments, the first extracellular domain of the chimeric signaling receptor comprises a functional fragment of FKBP, the rapamycin binding domain of FK binding protein 12. In some embodiments, the second extracellular domain of the chimeric signaling receptor comprises a functional fragment of FRB, i.e., the rapamycin binding domain of FKBP12-rapamycin binding domain of mTOR. A functional fragment of FKBP or FRB is a fragment that dimerizes with the corresponding fragment upon binding to a ligand (e.g., rapamycin or a rapalog).

[0031] In some embodiments, the chimeric signaling receptor provided herein controls signaling induced, propagated, or maintained by interleukins (ILs). In some embodiments, the ILs are members of the IL1 superfamily. ILs of the IL1 superfamily can include ILs of any subfamily, such as ILs that share IL-1RAP as a secondary receptor (e.g., IL1, IL33, or IL36), or IL18. In some embodiments, the signaling domain (e.g., the first membrane proximal signaling domain, the second membrane proximal signaling domain, the first membrane distal signaling domain, or the second membrane distal signaling domain) of the chimeric signaling receptor comprises an intracellular signaling domain or functional fragment of a receptor of an IL1 superfamily member (e.g., IL1, IL18, IL33, IL36, IL37, or IL38). Fields et al. (Front Immunol, 20 Jun. 2019; 10:1412) provides a description of IL1 superfamily signaling and its receptors. The entirety of this document is incorporated herein by reference.

[0032] In some embodiments, the first membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL1R (e.g., IL1RI, IL1RII, or IL1RAP), IL2Rβ, IL2Rγ, IL10R1, IL10R2, IL18R1, IL18RAP, ST2, IL36R, LIFR, or gp130. In some embodiments, the second membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL1R (e.g., IL1RI, IL1RII, or IL1RAP), IL2Rβ, IL2Rγ, IL10R1, IL10R2, IL18R1, IL18RAP, ST2, IL36R, LIFR, or gp130.

[0033] In some embodiments, the first membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL2Rβ (e.g., SEQ ID NO:5, 7) and the second membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL2Rγ (e.g., SEQ ID NO:8, 10). In some embodiments, the first membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL2Rγ (e.g., SEQ ID NO:4, 6) and the second membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL2Rβ (e.g., SEQ ID NO:9, 11). In some embodiments, the first transmembrane domain comprises a transmembrane domain of IL2Rβ and the second transmembrane domain comprises a transmembrane domain of IL2Rγ. In some embodiments, the first transmembrane domain and the second transmembrane domain each comprise a transmembrane domain of IL2Rβ. In some embodiments, the first transmembrane domain and the second transmembrane domain each comprise a transmembrane domain of IL2Rγ.

[0034] In some embodiments, the first membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of ST2 (e.g., SEQ ID NO: 9, 10) and the second membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL1RAP (e.g., SEQ ID NO: 4, 7). In some embodiments, the first membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL1RAP (e.g., SEQ ID NO: 8, 11) and the second membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of ST2 (e.g., SEQ ID NO: 5, 6). In some embodiments, the first membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of IL2Rβ (e.g., SEQ ID NO: 9, 11) and the second membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of IL2Rγ (e.g., SEQ ID NO: 8, 10). In some embodiments, the first membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of IL2Rγ (e.g., SEQ ID NO: 8, 10) and the second membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of IL2Rβ (e.g., SEQ ID NO: 9, 11).

[0035] In some embodiments, the first membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL36R and the second membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL1RAP (e.g., SEQ ID NO: 4). In some embodiments, the first membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL1RAP (e.g., SEQ ID NO: 4) and the second membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL36R.

[0036] In some embodiments, the first membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL18R1 and the second membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL18RAP. In some embodiments, the first membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL18RAP and the second membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL18R1.

[0037] In some embodiments, the first membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL10R1 (e.g., SEQ ID NO: 13, 15) and the second membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL10R2 (e.g., SEQ ID NO: 12, 14). In some embodiments, the first membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL10R2 and the second membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL10R1.

[0038] In some embodiments, the first membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of gp130 and the second membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of LIFrβ. In some embodiments, the first membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of LIFrβ and the second membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of gp130.

[0039] In some embodiments, the first membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of IL1R (e.g., IL1RI, IL1RII, or IL1RAP), IL2Rβ, IL2Rγ, IL10R1, IL10R2, IL18R1, IL18RAP, ST2, IL36R, LIFR, or gp130. In some embodiments, the second membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of IL1R (e.g., IL1RI, IL1RII, or IL1RAP), IL2Rβ, IL2Rγ, IL10R1, IL10R2, IL18R1, IL18RAP, ST2, IL36R, LIFR, or gp130.

[0040] In some embodiments, the first membrane proximal signaling domain and the second membrane proximal spacing domain are linked (e.g., using a comparable sized extracellular linker and / or membrane proximal linker) to the first extracellular domain and the second extracellular domain, respectively, allowing these signaling domains to effect downstream signaling (e.g., phosphorylation of Jak1 and Jak3 in the case of IL2R signaling). In some embodiments, the first membrane distal signaling domain and the second membrane distal spacing domain are further linked (e.g., using a comparable sized membrane distal linker) to the first extracellular domain (and the first membrane proximal domain) and the second extracellular domain (and the second membrane proximal domain), respectively, allowing all four signaling domains to effect downstream signaling (e.g., phosphorylation of Jak1 and Jak3 and activation of MyD88 in the case of IL2R signaling).

[0041] The chimeric signaling receptor of the present disclosure may have any configuration of the first and second membrane proximal signaling domains and the first and second membrane proximal signaling domains. For example, the first and second membrane proximal signaling domains may provide IL2R signaling, and the first and second membrane distal signaling domains may provide ST2 signaling. As another non-limiting example, the first and second membrane proximal signaling domains may provide ST2 signaling, and the first and second membrane distal signaling domains may provide IL2 signaling. Furthermore, the membrane proximal binding domain and the membrane distal binding domain may be linked to any extracellular domain. For example, a first polypeptide comprising an IL2Rβ signaling domain and an ST2 signaling domain may further comprise an FKBP, and a second polypeptide comprising an IL2Rγ signaling domain and an IL1RAP signaling domain may further comprise an FRB. Alternatively, a first polypeptide comprising an IL2Rβ and an ST2 signaling domain may further comprise an FRB, and a second polypeptide comprising an IL2Rγ and an IL1RAP signaling domain may further comprise an FKBP.

[0042] In some embodiments, the first membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of IL2Rβ and the second membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of IL2Rγ. In some embodiments, the first membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of IL2Rγ and the second membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of IL2Rβ.

[0043] In some embodiments, the first membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of ST2 and the second membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of IL1RAP. In some embodiments, the first membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of IL1RAP and the second membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of ST2.

[0044] In some embodiments, the first membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of IL36R and the second membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of IL1RAP. In some embodiments, the first membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of IL1RAP and the second membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of IL36R.

[0045] In some embodiments, the first membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of IL18R1 and the second membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of IL18RAP. In some embodiments, the first membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of IL18RAP and the second membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of IL18R1.

[0046] In some embodiments, the first membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of IL10R1 and the second membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of IL10R2. In some embodiments, the first membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of IL10R2 and the second membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of IL10R1.

[0047] In some embodiments, the first membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of gp130 and the second membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of LIFrβ. In some embodiments, the first membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of LIFrβ and the second membrane distal signaling domain comprises an intracellular signaling domain or functional fragment of gp130.

[0048] In some embodiments, the transmembrane domain (e.g., a first transmembrane domain or a second transmembrane domain) comprises a transmembrane domain or a fragment of a transmembrane domain of IL1R (e.g., IL1RI, IL1RII, or IL1RAP), IL2Rβ, IL2Rγ, IL10R1, IL10R2, IL18R1, IL18RAP, ST2, IL36R, LIFR, or gp130. In some embodiments, the transmembrane domain of IL2Rβ, IL2Rγ, IL10R1, IL10R2, IL18R1, IL18RAP, ST2, IL1RAP, LIFR, or gp130 comprises a portion that extends into the cytoplasm of a native cell in which it is expressed and / or a portion that extends into the extracellular space relative to a native cell in which it is expressed. In some embodiments, a chimeric signaling receptor polypeptide (e.g., a first or second polypeptide) comprises a transmembrane domain or a fragment thereof and an intracellular signaling domain or a functional fragment thereof of the same receptor polypeptide (e.g., a transmembrane domain and an intracellular signaling domain of ST2). In some embodiments, a chimeric signaling receptor polypeptide (e.g., a first or second polypeptide) comprises a transmembrane domain or a fragment thereof and an intracellular signaling domain or a functional fragment thereof of a different receptor polypeptide (e.g., a transmembrane domain of IL1RAP and an intracellular signaling domain of ST2).

[0049] In some embodiments, the extracellular linker (e.g., the first or second extracellular linker) that links the extracellular domain and the transmembrane domain comprises a peptide (e.g., a human peptide or an artificial peptide). In some embodiments, the extracellular linker (e.g., the first or second extracellular linker) that links the extracellular domain and the transmembrane domain comprises a synthetic linker (e.g., a flexible linker) or an extracellular hinge domain. In some embodiments, the linker is a flexible linker or a rigid linker. In some embodiments, the linker is a flexible linker. In some embodiments, the linker comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids (e.g., glycines), or a number of amino acids (e.g., glycines) within a range defined by any two of the preceding numbers. In some embodiments, the Gly spacer comprises at least 3 Gly. In some embodiments, the Gly spacer comprises a sequence depicted as GGGS (SEQ ID NO: 20), GGGSGGG (SEQ ID NO: 21), or GGG. In principle, to provide flexibility, flexible linkers usually contain small non-polar (e.g., Gly) or polar (e.g., Ser or Thr) amino acids, e.g., a basic sequence of alternating Gly and Ser residues. The solubility of the linker and associated chimeric signaling receptors can be improved by including charged residues, e.g., two positively charged residues (Lys) and one negatively charged residue (Glu). Linkers vary from 2 to 31 amino acids and are optimized for each condition, so that linkers do not impose any constraints on the structure or interactions of the linked partners, with lengths such as 12 to 18 residues.

[0050] In some embodiments, the extracellular binding domain may be attached to the transmembrane domain via a hinge domain ("hinge"). Hinge refers to a domain that links the extracellular binding domain to the transmembrane domain and may confer flexibility to the extracellular binding domain. In some embodiments, the hinge domain positions the extracellular domain close to the plasma membrane, minimizing the possibility of recognition by an antibody or binding fragment thereof. In some embodiments, the hinge domain may be natural or synthetic.

[0051] In some embodiments, the extracellular linker (e.g., the first or second extracellular linker) connecting the extracellular domain and the transmembrane domain comprises a (G4S)xN (SEQ ID NO:22) peptide linker (where N can be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more) or an extracellular hinge of IL1R (e.g., IL1RI, IL1RII, or IL1RAP), IL2Rβ, IL2Rγ, IL10R1, IL10R2, IL18R1, IL18RAP, ST2, IL38R, LIFrβ, or gp130. In some embodiments, the first extracellular hinge domain is from IL10R1 and the second extracellular hinge domain is from IL10R2.

[0052] In some embodiments, the membrane proximal linker (e.g., the first or second extracellular linker) connecting the transmembrane domain and the membrane proximal signaling domain comprises a peptide (e.g., a human peptide or an artificial peptide). In some embodiments, the membrane proximal linker (e.g., the first or second extracellular linker) connecting the transmembrane domain and the membrane proximal signaling domain comprises a (G4S)xN (SEQ ID NO:22) peptide linker (where N can be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more) or the intracellular hinge / domain of IL1R (e.g., IL1RI, IL1RII, or IL1RAP), IL2Rβ, IL2Rγ, IL10R1, IL10R2, IL18R1, IL18RAP, ST2, IL36R, LIFrβ, or gp130.

[0053] In some embodiments, the membrane distal linker (e.g., the first or second extracellular linker) connecting the membrane proximal signaling domain to the membrane distal signaling domain comprises a peptide (e.g., a human peptide or an artificial peptide). In some embodiments, the membrane distal linker (e.g., the first or second extracellular linker) connecting the membrane proximal signaling domain to the membrane distal signaling domain comprises a (G4S)xN (SEQ ID NO:22) peptide linker (where N can be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more) or the intracellular hinge / domain of IL1R (e.g., IL1RI, IL1RII, or IL1RAP), IL2Rβ, IL2Rγ, IL10R1, IL10R2, IL18R1, IL18RAP, ST2, IL36R, LIFrβ, or gp130.

[0054] In some embodiments, any of the extracellular domain, transmembrane domain, membrane proximal signaling domain, membrane distal signaling domain, extracellular linker, membrane proximal linker, and membrane distal linker of the chimeric signaling receptor polypeptide are derived from a human protein. In some embodiments, any of the extracellular domain, transmembrane domain, membrane proximal signaling domain, membrane distal signaling domain, extracellular linker, membrane proximal linker, and membrane distal linker of the chimeric signaling receptor polypeptide are derived from a non-human source, such as a mouse protein. In some embodiments, any of the extracellular domain, transmembrane domain, membrane proximal signaling domain, membrane distal signaling domain, extracellular linker, membrane proximal linker, and membrane distal linker of the chimeric signaling receptor polypeptide are derived from the same naturally occurring receptor polypeptide.

[0055] In some aspects, provided herein are chimeric signaling receptors for controlling cell signaling involved in proliferation, cell division and replication, DNA replication, protein synthesis, cytokine production, maintenance of a cytotoxic phenotype (e.g., as observed in cytotoxic T cells), maintenance of a regulatory phenotype (e.g., as observed in regulatory T cells), cell homing, antigen recognition and activation, or tissue repair, such as repair regulatory T (Treg) cells. In some embodiments, the chimeric signaling receptor comprises a signaling domain involved in signaling following receptor binding of IL1 to IL1R or activation of the IL1R receptor, signaling following receptor binding of IL33 to ST2 or activation of the ST2 receptor, signaling following receptor binding of IL18 to the IL18 receptor or activation of the IL18 receptor, signaling following receptor binding of IL36 to IL36R or activation of the IL36R receptor, signaling following receptor binding of IL2 to the IL2 receptor or activation of the IL2 receptor, signaling following receptor binding of IL10 to the IL10 receptor or activation of the IL10 receptor, signaling following receptor binding of LIF to the LIF receptor or activation of the LIF receptor.

[0056] In some embodiments, the IL2 receptor is activated, resulting in IL2 signaling, which leads to STAT5 phosphorylation and Treg proliferation. Furthermore, IL2 signaling plays a role in immune homeostasis, and dysregulation of IL2 signaling has been identified as a contributing factor in autoimmune diseases and immune deficiencies. In some embodiments, a chimeric signaling receptor for controlling IL2 signaling comprises a first polypeptide and a second polypeptide, the first polypeptide comprising a first extracellular domain, a first transmembrane domain, and a first membrane proximal signaling domain, and the second polypeptide comprising a second extracellular domain, a second transmembrane domain, and a second membrane proximal signaling domain.

[0057] In some embodiments, the first extracellular domain comprises FKBP or a functional fragment thereof and the second extracellular domain comprises FRB or a functional fragment thereof. In some embodiments, the first membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL2Rβ and the second membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL2Rγ. In some embodiments, the first membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL2Rγ and the second membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL2Rβ.

[0058] In some embodiments, provided herein is a chimeric signaling receptor for controlling IL33 or ST2 signaling. Upon binding to ST2, IL33 activates MyD88, IRAK1, and TRAF6 pathways, resulting in activation of downstream NF-κB, JNK, p38, and ERK signaling pathways. This activation enhances Foxp3 and GATA expression, Treg function, proliferation of ST2+ Tregs, and production of type 2 cytokines (e.g., IL5 and IL13). IL33 or ST2+ Tregs are involved in tissue (e.g., lung tissue) repair, reducing inflammation, and can migrate and proliferate upon activation (e.g., by IL33). Thus, in some aspects, provided herein is a chimeric signaling receptor for controlling IL33 or ST2 signaling.

[0059] In some embodiments, a chimeric signaling receptor for controlling ST2 signaling comprises a first polypeptide and a second polypeptide, the first polypeptide comprises a first extracellular domain, a first transmembrane domain, and a first membrane proximal signaling domain, and the second polypeptide comprises a second extracellular domain, a second transmembrane domain, and a second membrane proximal signaling domain.

[0060] In some embodiments, the first extracellular domain comprises FKBP or a functional fragment thereof and the second extracellular domain comprises FRB or a functional fragment thereof. In some embodiments, a first membrane proximal domain of a chimeric signaling receptor for controlling ST2 signaling comprises an intracellular signaling domain or functional fragment of ST2, and a second membrane proximal domain of a chimeric signaling receptor for controlling ST2 signaling comprises an intracellular signaling domain or functional fragment of IL1RAP. In some embodiments, a first membrane proximal domain of a chimeric signaling receptor for controlling ST2 signaling comprises an intracellular signaling domain or functional fragment of IL1RAP, and a second membrane proximal domain of a chimeric signaling receptor for controlling ST2 signaling comprises an intracellular signaling domain or functional fragment of ST2.

[0061] It will be understood that any configuration of extracellular domains and signaling domains including membrane proximal and membrane distal domains of the first and second polypeptides of the chimeric signaling receptor is contemplated herein. In some embodiments, the chimeric signaling receptor comprises two signaling domains in each polypeptide. For example, the first and second membrane proximal signaling domains may comprise the intracellular receptor domain of ST2, and the first and second membrane distal signaling domains may comprise the intracellular receptor domain of IL2R. Alternatively, the chimeric signaling receptor may comprise the first and second membrane proximal signaling domains comprising the intracellular receptor domain of IL2R and the first and second membrane distal signaling domains comprising the intracellular receptor domain of ST2.

[0062] In some embodiments, a chimeric signaling receptor for controlling ST2 signaling comprises a first membrane proximal signaling domain comprising the intracellular signaling domain or functional fragment of ST2, a second membrane proximal signaling domain comprising the intracellular signaling domain or functional fragment of IL1RAP, a first membrane distal signaling domain comprising the intracellular signaling domain or functional fragment of IL2Rβ, and a second membrane distal signaling domain comprising the intracellular signaling domain or functional fragment of IL2Rγ.

[0063] In some embodiments, a chimeric signaling receptor for controlling ST2 signaling comprises a first membrane proximal signaling domain comprising the intracellular signaling domain or functional fragment of IL1RAP, a second membrane proximal signaling domain comprising the intracellular signaling domain or functional fragment of ST2, a first membrane distal signaling domain comprising the intracellular signaling domain or functional fragment of IL2Rβ, and a second membrane distal signaling domain comprising the intracellular signaling domain or functional fragment of IL2Rγ.

[0064] In some embodiments, a chimeric signaling receptor for controlling ST2 signaling comprises a first membrane proximal signaling domain comprising the intracellular signaling domain or functional fragment of ST2, a second membrane proximal signaling domain comprising the intracellular signaling domain or functional fragment of IL1RAP, a first membrane distal signaling domain comprising the intracellular signaling domain or functional fragment of IL2Rγ, and a second membrane distal signaling domain comprising the intracellular signaling domain or functional fragment of IL2Rβ.

[0065] In some embodiments, a chimeric signaling receptor for controlling ST2 signaling comprises a first membrane proximal signaling domain comprising the intracellular signaling domain or functional fragment of IL1RAP, a second membrane proximal signaling domain comprising the intracellular signaling domain or functional fragment of ST2, a first membrane distal signaling domain comprising the intracellular signaling domain or functional fragment of IL2Rγ, and a second membrane distal signaling domain comprising the intracellular signaling domain or functional fragment of IL2Rβ.

[0066] In some embodiments, chimeric signaling receptors are provided for controlling IL18 signaling. Upon binding to its receptor, IL18 signals through the MyD88 / NF-κB signaling pathway. IL18 or IL18 receptor (IL18R) signaling is involved in tissue repair and reducing inflammation (e.g., in the lung and intestine). It is also involved in suppressing intestinal inflammation. Thus, in some aspects, chimeric signaling receptors are provided herein for controlling IL18 or IL18R signaling.

[0067] In some embodiments, a chimeric signaling receptor for controlling IL18R signaling comprises a first polypeptide and a second polypeptide, the first polypeptide comprises a first extracellular domain, a first transmembrane domain, and a first membrane proximal signaling domain, and the second polypeptide comprises a second extracellular domain, a second transmembrane domain, and a second membrane proximal signaling domain. In some embodiments, the first polypeptide further comprises a first membrane distal signaling domain, and the second polypeptide further comprises a second membrane distal signaling domain. The IL18R domain can be comprised in either the membrane proximal signaling domain of the receptor polypeptide or the membrane distal signaling domain of the receptor polypeptide.

[0068] In some embodiments, the first extracellular domain comprises FKBP or a functional fragment thereof, and the second extracellular domain comprises FRB or a functional fragment thereof. In some embodiments, the first membrane proximal domain of the chimeric signaling receptor for regulating IL18R signaling comprises an intracellular signaling domain or a functional fragment of IL18R1, and the second membrane proximal domain of the chimeric signaling receptor for regulating IL18R signaling comprises an intracellular signaling domain or a functional fragment of IL18RAP. In some embodiments, the first membrane proximal domain of the chimeric signaling receptor for regulating IL18R signaling comprises an intracellular signaling domain or a functional fragment of IL18RAP, and the second membrane proximal domain of the chimeric signaling receptor for regulating IL18R signaling comprises an intracellular signaling domain or a functional fragment of IL18R1.

[0069] In some embodiments, chimeric signaling receptors are provided for controlling leukemia inhibitory factor (LIF) signaling. LIF binds to the LIF receptor (LIFR) and recruits gpl30, activating JAK / STAT3, PI3K / AKT, ERK1 / 2, and mTOR downstream signaling pathways. These pathways support immune tolerance, promote tissue repair, induce Foxp3 expression, and promote allogeneic tolerance. Thus, in some aspects, chimeric signaling receptors are provided herein for controlling LIF or LIFR signaling.

[0070] In some embodiments, a chimeric signaling receptor for controlling LIFR signaling comprises a first polypeptide and a second polypeptide, the first polypeptide comprises a first extracellular domain, a first transmembrane domain, and a first membrane proximal signaling domain, and the second polypeptide comprises a second extracellular domain, a second transmembrane domain, and a second membrane proximal signaling domain. In some embodiments, the first polypeptide further comprises a first membrane distal signaling domain, and the second polypeptide further comprises a second membrane distal signaling domain. The LIFR domain can be comprised in either the membrane proximal signaling domain of the receptor polypeptide or the membrane distal signaling domain of the receptor polypeptide.

[0071] In some embodiments, the first extracellular domain comprises FKBP or a functional fragment thereof and the second extracellular domain comprises FRB or a functional fragment thereof. In some embodiments, a first membrane proximal domain of a chimeric signaling receptor for controlling LIFR signaling comprises an intracellular signaling domain or functional fragment of gl30 and a second membrane proximal domain of a chimeric signaling receptor for controlling LIFR signaling comprises an intracellular signaling domain or functional fragment of LIFrβ. In some embodiments, a first membrane proximal domain of a chimeric signaling receptor for controlling LIFR signaling comprises an intracellular signaling domain or functional fragment of LIFrβ and a second membrane proximal domain of a chimeric signaling receptor for controlling LIFR signaling comprises an intracellular signaling domain or functional fragment of gpl30.

[0072] In some embodiments, chimeric signaling receptors are provided for controlling IL10 or IL10R signaling. IL10 or IL10R signaling is involved in the suppressive phenotype of Tr1 cells and has a broad impact on tolerance induction in inflammatory diseases such as irritable bowel disease (IBD) and Crohn's disease. Thus, in some aspects, chimeric signaling receptors are provided herein for controlling IL10 or IL10R signaling.

[0073] In some embodiments, a chimeric signaling receptor for controlling IL10R signaling comprises a first polypeptide and a second polypeptide, the first polypeptide comprises a first extracellular domain, a first transmembrane domain, and a first membrane proximal signaling domain, and the second polypeptide comprises a second extracellular domain, a second transmembrane domain, and a second membrane proximal signaling domain. In some embodiments, the first polypeptide further comprises a first membrane distal signaling domain, and the second polypeptide further comprises a second membrane distal signaling domain. The IL10R domain can be comprised in either the membrane proximal signaling domain of the receptor polypeptide or the membrane distal signaling domain of the receptor polypeptide.

[0074] In some embodiments, the first extracellular domain comprises FKBP or a functional fragment thereof and the second extracellular domain comprises FRB or a functional fragment thereof. In some embodiments, a first membrane proximal domain of a chimeric signaling receptor for controlling IL10R signaling comprises an intracellular signaling domain or functional fragment of IL10R1 and a second membrane proximal domain of a chimeric signaling receptor for controlling IL10R signaling comprises an intracellular signaling domain or functional fragment of IL10R2. In some embodiments, a first membrane proximal domain of a chimeric signaling receptor for controlling IL10R signaling comprises an intracellular signaling domain or functional fragment of IL10R2 and a second membrane proximal domain of a chimeric signaling receptor for controlling IL10R signaling comprises an intracellular signaling domain or functional fragment of IL10R1.

[0075] 9A-9H show examples of amino acid sequences of chimeric signaling receptors provided herein. A chimeric signaling receptor, or a domain thereof (e.g., a first polypeptide, a first extracellular domain, a first transmembrane domain, a first membrane proximal signaling domain, a first membrane distal signaling domain, a first extracellular linker, a first membrane proximal linker, a first membrane distal linker, a first signal peptide, a second polypeptide, a second extracellular domain, a second transmembrane domain, a second membrane proximal signaling domain, a second membrane distal signaling domain, a second extracellular linker, a second membrane proximal linker, a second membrane distal linker, or a second signal peptide) can include a polypeptide having at least 50% identity (e.g., at least 50, at least 60, at least 70, at least 80, at least 90, at least 95, at least 98, at least 99, or at least 99.5% identity) to any of the amino acid sequences shown in FIG. 9A-9H.

[0076] Compositions for producing genetically engineered cells In some aspects, provided herein are compositions for genetically engineering cells with any one of the chimeric signaling receptors described herein, either in vitro, in vivo, or ex vivo.

[0077] In some embodiments, provided herein is a nucleic acid comprising a polynucleotide encoding any one of the chimeric signaling receptor polypeptides disclosed herein. In some embodiments, provided herein is a nucleic acid comprising a polynucleotide encoding a first polypeptide of any one of the chimeric signaling receptors provided herein. In some embodiments, provided herein is a nucleic acid comprising a polynucleotide encoding a second polypeptide of any one of the chimeric signaling receptors provided herein. In some embodiments, provided herein is a nucleic acid comprising a first polynucleotide encoding a first polypeptide of any one of the chimeric signaling receptors provided herein and a second polynucleotide encoding a second polypeptide of any one of the chimeric signaling receptors provided herein.

[0078] In some embodiments, a nucleic acid comprising a polynucleotide encoding any one of the chimeric signaling receptor polypeptides further comprises one or more regulatory elements, such as a promoter, operably linked to the one or more polynucleotides. The promoter can be a constitutive promoter or an inducible promoter.

[0079] In some embodiments, the composition for engineering cells according to the methods disclosed herein further comprises one or more nucleic acids encoding a T cell receptor (TCR), a chimeric antigen receptor (CAR) to target specific cells, enhance suppressive function, or both. In some embodiments, the composition comprises a nucleic acid encoding IL-2. In some embodiments, the composition for generating engineered cells according to the methods disclosed herein comprises a nucleic acid encoding constitutively active IL-10 (see, e.g., WO 2019 / 180724, which is incorporated herein by reference in its entirety), a CISC component, and / or a soluble FRB protein uncoupled from mTOR (see, e.g., WO 2018 / 111834, WO 2019 / 210057, and WO 2020 / 264039, which are incorporated herein by reference in their entirety).

[0080] In some embodiments, the nucleic acids described herein (e.g., for introduction into a cell or administration to a subject) are included in a vector. The term "vector" is used to refer to any molecule (e.g., nucleic acid, plasmid) or assortment of molecules (such as a virus) used to deliver coding information to a host cell. The term "expression vector" refers to a vector suitable for introduction into a host cell and containing a nucleic acid sequence that induces and / or controls the expression of an introduced heterologous nucleic acid sequence. Expression includes, but is not limited to, processes such as transcription, translation, and RNA splicing when introns are present. Non-limiting examples of vectors include artificial chromosomes, minigenes, cosmids, plasmids, phagemids, and viral vectors. Non-limiting examples of viral vectors include lentiviral vectors, retroviral vectors, herpes viral vectors, adenoviral vectors, and adeno-associated viral vectors. In some embodiments, one or more vectors containing a nucleic acid used in the methods provided herein are lentiviral vectors. In some embodiments, one or more vectors are adenoviral vectors. In some embodiments, one or more vectors are adeno-associated viral (AAV) vectors. In some embodiments, one or more AAV vectors are AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, or AAV11 vectors. In some embodiments, one or more AAV vectors are AAV5 vectors. In some embodiments, one or more AAV vectors are AAV6 vectors.

[0081] As will be appreciated by those of skill in the art, nucleic acids can include genomic, extragenomic and plasmid-encoded sequences, as well as smaller artificial gene segments that express, or can be adapted to express, proteins, polypeptides, peptides, etc. Such segments can be naturally isolated or synthetically modified by one of skill in the art.

[0082] As will also be appreciated by those skilled in the art, polynucleotides can be single-stranded (coding or antisense) or double-stranded, and can be DNA (genomic, cDNA or synthetic) or RNA molecules. RNA molecules can include HnRNA molecules, which contain introns and correspond one-to-one to DNA molecules, and mRNA molecules, which do not contain introns. Additional coding or non-coding sequences may, but need not, be present within a polynucleotide in accordance with the present disclosure, and polynucleotides may, but need not, be linked to other molecules and / or supporting materials. Polynucleotides may include naturally occurring sequences or may include sequences that encode variants or derivatives of such sequences.

[0083] In some embodiments, a polynucleotide variant may have substantial identity with a reference polynucleotide sequence encoding an immunomodulatory polypeptide as described herein. For example, a polynucleotide may comprise at least 70% sequence identity, preferably at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or more sequence identity, or sequence identity within a range defined by any two of the aforementioned percentages, compared to a reference polynucleotide sequence, such as a sequence encoding an antibody as described herein, using methods described herein (e.g., BLAST analysis using standard parameters as described below). Those skilled in the art will recognize that the corresponding identity of proteins encoded by two nucleotide sequences can be determined by appropriately adjusting these values ​​to take into account codon degeneracy, amino acid similarity, reading frame position, etc.

[0084] Typically, a polynucleotide variant will contain one or more substitutions, additions, deletions and / or insertions, preferably such that it is capable of specific binding interactions with another molecule and the binding affinity of a polypeptide variant for a given polypeptide encoded by the variant polynucleotide is not substantially reduced compared to the polypeptides encoded by the polynucleotide sequences specifically described herein.

[0085] Some embodiments of the nucleic acid sequences described herein (e.g., nucleic acid, vector, or intracellular sequences) are codon-optimized for expression in a cell. The term "codon optimization" with respect to a gene or coding sequence present in or introduced into a host cell refers to changing the codons in the gene or coding sequence to reflect the general codon usage of the host cell without changing the amino acid sequence encoded by the gene or coding sequence. Such optimization includes replacing at least one, or more than one, or a substantial number of codons with one or more codons that are more frequently used in genes of that organism. Codon usage tables are readily available, for example, at the "Codon Usage Database" at www.kazusa.or.jp. Using knowledge of the codon usage or codon preference in each organism, one of skill in the art can apply the frequency to any polypeptide with a given amino acid sequence to create a codon-optimized coding sequence that encodes the same polypeptide with the same amino acid sequence but that uses the optimal codons for a given species (e.g., human). Codon-optimized coding regions can be designed by a variety of methods known to those of skill in the art.

[0086] Regardless of the length of the coding sequence itself, the polynucleotides described herein or fragments thereof can be combined with other DNA sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, etc., so that the overall length can vary significantly. Thus, it is contemplated that nucleic acid fragments of almost any length can be used, but the total length is preferably limited by the ease of preparation and use in the intended recombinant DNA protocol. For example, exemplary polynucleotide segments with total lengths of about 10,000, 5000, 3000, 2,000, 1,000, 500, 200, 100, or 50 base pairs, etc. (including all intermediate lengths) are contemplated to be useful.

[0087] When comparing sequences of polynucleotides or nucleic acids, two sequences are said to be "identical" if the sequences of nucleotides of the two sequences are the same when aligned for maximum correspondence, as described below. Comparison of two sequences is typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity. As used herein, a "comparison window" refers to a segment of at least about 20 contiguous positions, typically 30-75, or 40-50 contiguous positions, in which a sequence can be compared to a reference sequence having the same number of contiguous positions after optimal alignment of the two sequences.

[0088] Optimal alignment of sequences for comparison can be performed using the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR, Inc., Madison, Wis.), using default parameters. This program incorporates several alignment schemes, as described in the following references: Dayhoff, MO (1978) A model of evolutionary change in proteins-Matrices for detecting distance relationships. Dayhoff, MO (ed.) Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, Washington DC Vol. 5, Suppl. 3, pp. 345-358; Hein J., Unified Approach to Alignment and Phylogenes, pp. 626-645 (1990); Methods in Enzymology vol. 183, Academic Press, Inc., San Diego, CA; Higgins, DGand Sharp, PM, CABIOS 5:151-153(1989); Myers, EWand Muller W., CABIOS 4:11-17(1988); Robinson, ED, Comb. Theor 11:105(1971);Santou,N.Nes,M.,Mol.Biol.Evol.4:406-425(1987);Sneath,PHAand Sokal, RR, Numerical Taxonomy-the Principles and Practice of Numerical Taxonomy, Freeman Press, San Francisco, CA (1973); Wilbur, W Jand Lipman, DJ, Proc. Natl. Acad., Sci. USA 80:726-730 (1983).

[0089] Alternatively, optimal alignment of sequences for comparison can be performed by the local identity algorithm of Smith and Waterman, Add. APL. Math 2:482 (1981), by the identity alignment algorithm of Needleman and Wunsch, J. Mol. Biol. 48:443 (1970), by the similarity search method of Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85:2444 (1988), by computer implementations of these algorithms (GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, WI), or by inspection.

[0090] One preferred example of an algorithm suitable for determining the percentage of sequence identity and sequence similarity is the BLAST and BLAST 2.0 algorithms described in Altschul et al., Nucl Acids Res. 1977.25:3389-3402, and Altschul et al., J Mol Biol. 1990.215:403-410, respectively. BLAST and BLAST 2.0 can be used to determine the percentage of sequence identity between two or more polynucleotides, for example, using the parameters described herein. Software for performing BLAST analysis is publicly available through the National Center for Biotechnology Information (NCBI). As an example, for nucleotide sequences, the cumulative score can be calculated using the parameters M (reward score for a pair of matching residues, always >0) and N (penalty score for mismatching residues, always <0). Extension of the word hits in each direction is stopped when the cumulative alignment score falls by an amount X from the maximum achieved, when the accumulation of one or more negative scoring residue alignments causes the cumulative score to fall below zero, or when the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, the BLOSUM62 scoring matrix (see Henikoff and Henikoff, Proc Natl Acad Sci USA. 1989.89:10915) alignment, (B) of 50, an expectation (E) of 10, M=5, N=-4, and a comparison of both strands.

[0091] In certain embodiments, the "percentage of sequence identity" is determined by comparing two optimally aligned sequences over a comparison window of at least 20 positions, where the portion of the polynucleotide sequence within the comparison window can contain no more than 20 percent, typically 5-15 percent, or 10-12 percent, additions or deletions (i.e., gaps) compared to the reference sequence (which does not contain additions or deletions) for optimal alignment of the two sequences. This percentage is calculated by determining the number of positions at which identical nucleobases are found in both sequences to obtain the number of matched positions, dividing the number of matched positions by the total number of positions in the reference sequence (i.e., the window size), and multiplying the result by 100 to calculate the percentage of sequence identity.

[0092] Standard techniques can be used for recombinant DNA, oligonucleotide synthesis, tissue culture and transformation (e.g., electroporation, lipofection). Enzymatic reactions and purification techniques can be performed according to manufacturer's specifications or as commonly practiced in the art or as described herein. These and related techniques and procedures can generally be performed according to conventional methods well known in the art, as well as the methods described in the various general and more specific references cited and described throughout the specification. Unless specific definitions are provided, the nomenclature used in connection with molecular biology, analytical chemistry, organic synthetic chemistry, medicinal and pharmaceutical chemistry, and the laboratory procedures and techniques thereof described herein are those well known and commonly used in the art. Standard techniques can be used for recombinant technology, molecular biology, microbiology, chemical synthesis, chemical analysis, pharmaceutical preparation, formulation, delivery, and treatment of patients.

[0093] Cell types In some aspects, provided herein is a cell comprising any one of the nucleic acid molecules described herein, any one of the viral vectors described herein, or any one of the polypeptides described herein. In some aspects, provided herein is a cell comprising any one of the polypeptides of the chimeric signaling receptors provided herein, and / or one or more nucleic acids comprising a polynucleotide encoding one or more polypeptides of the chimeric signaling receptors provided herein. In some embodiments, the cell provided herein is a therapeutic cell, e.g., a cell prepared for administration to a subject (e.g., a human subject). The cell may be one of a number of cells cultured under certain conditions, or may be part of a harvested organ, part of an organoid, or an organism. In some embodiments, the cell disclosed herein is a eukaryotic cell (derived from a eukaryotic organism).

[0094] Embodiments of the methods of producing genetically modified cells (e.g., by in vitro or ex vivo gene editing, and / or by administering a composition, vector, or nucleic acid to a subject for in vivo editing) can use any cell type known in the art, e.g., as a source for introduction of a nucleic acid, vector, and / or composition. It is understood that the methods described herein, including manipulation of CD4+ cells, can also be applied to other types of cells (e.g., CD25+, CD3+, CD8+, Foxp3+, and / or IL10 / IL10R+ cells). In some embodiments, the methods described herein include editing immune cells. Non-limiting examples of immune cells include B cells, T cells, and NK cells. In some embodiments, the methods provided herein include editing CD3+ cells, thereby producing edited CD3+ cells, including CD4+ and CD8+ Treg cells. In some embodiments, the methods include editing CD4+ T cells, thereby producing CD4+ Treg cells. In some embodiments, the methods include editing CD8+ T cells, thereby producing CD8+ Treg cells.

[0095] In some embodiments, the method includes editing a stem cell. In some embodiments, the method includes editing a pluripotent stem cell. In some embodiments, the method includes editing a CD34+ hematopoietic stem cell (HSC). In some embodiments, the method includes editing an induced pluripotent stem cell (iPSC). The edited stem cell can be matured in vitro to generate Treg cells or administered to a subject to develop into Treg cells in vivo. The edited stem cell can be matured into CD3+ Treg cells, CD4+ Treg cells, CD8+ Treg cells, or a combination thereof.

[0096] In some embodiments, the method includes editing T cells. T cells or T lymphocytes are immune system cells that mature in the thymus and generate T cell receptors (TCRs), such as antigen-specific heterodimeric cell surface receptors that are usually composed of α-β or γ-δ heterodimers. T cells of a given clonality usually express only a single TCR clonotype that recognizes a particular antigen epitope presented by a cognate antigen-presenting cell in the context of determinants encoded by the major histocompatibility complex. T cells can be naive ("TN", not exposed to antigen; increased expression of CD62L, CCR7, CD28, CD3, CD127, and CD45RA, reduced or absent expression of CD45RO compared to TCM (described herein), memory T cells (TM) (antigen-experienced and long-lived), including stem cell memory T cells, and effector cells (antigen-experienced, cytotoxic). TM can be further divided into subsets of central memory T cells (TCM, expressing CD62L, CCR7, CD28, CD95, CD45RO, and CD127) and effector memory T cells (TEM, expressing CD45RO and reduced expression of CD62L, CCR7, CD28, and CD45RA). Effector T cells (TE) are antigen-experienced CD8+ cytotoxic T lymphocytes that express CD45RA, have reduced expression of CD62L, CCR7, and CD28 compared to TCM, and are positive for granzymes and perforin. Helper T cells (TH) are CD4+ cells that affect the activity of other immune cells by releasing cytokines. CD4+ T cells can both activate and suppress adaptive immune responses, and which of these two functions is induced depends on the presence of other cells and signals. T cells can be collected using known techniques, and various subpopulations or combinations thereof can be enriched or depleted by known techniques, for example, using antibodies that specifically recognize one or more T cell surface phenotypic markers, by affinity binding to the antibodies, flow cytometry, fluorescence activated cell sorting (FACS), or immunomagnetic bead selection.Other exemplary T cells include regulatory T cells (Tregs, also called suppressor T cells), such as CD4+ CD25+ (FoxP3+) regulatory T cells and Tregl7 cells, as well as Tr1, Th3, CD8+ CD28-, or Qa-1 restricted T cells. In some embodiments, the cells are CD3+, CD4+, and / or CD8+ T cells. In some embodiments, the cells are CD3+ T cells. In some embodiments, the cells are CD4. + CD8 - In some embodiments, the cells are CD4 - CD8 + The cell is a T cell. In some embodiments, the cell is a regulatory T cell (Treg). Non-limiting examples of Treg cells are Tr1, Th3, CD8+CD28-, and Qa-1 restricted T cells. In some embodiments, the Treg cell is a FoxP3+ Treg cell. In some embodiments, the Treg cell expresses CTLA-4, LAG-3, CD25, CD39, CD27, CD70, CD357 (GITR), neuropilin-1, galectin-1, and / or IL-2Rα on its surface.

[0097] In some embodiments, the cells are human cells. In some embodiments, the cells described herein are isolated from a biological sample. The biological sample may be a sample from a subject (e.g., a human subject) or a composition (e.g., a cell culture) generated in a laboratory. The biological sample obtained from a subject may be a liquid sample (e.g., blood or a portion thereof, bronchial lavage fluid, cerebrospinal fluid, or urine) or a solid sample (e.g., a tissue slice). In some embodiments, the cells are obtained from peripheral blood. In some embodiments, the cells are obtained from umbilical cord blood. In some embodiments, the cells are obtained by sorting cells from peripheral blood to obtain a desired cell population (e.g., CD3+ cells), and one or more cells of the sorted population are modified by the methods described herein. Also contemplated herein are cells generated by the methods described herein.

[0098] The genetically modified cell embodiments described herein can be of any cell type known in the art. In some embodiments, the cell is a T cell, a progenitor T cell, or a hematopoietic stem cell. In some embodiments, the cell is a NK-T cell (e.g., a FoxP3-NK-T cell or a FoxP3+NK-T cell). In some embodiments, the cell is a regulatory B (Breg) cell (e.g., a FoxP3-B cell or a FoxP3+B cell). In some embodiments, the cell is a CD4+T cell (e.g., a FoxP3-CD4+T cell or a FoxP3+CD4+T cell) or a CD8+T cell (e.g., a FoxP3-CD8+T cell or a FoxP3+CD8+T cell). In some embodiments, the cell is a CD25-T cell. In some embodiments, the cell is a regulatory T (Treg) cell. Non-limiting examples of Treg cells are Tr1, Th3, CD8+CD28-, and Qa-1 restricted T cells. In some embodiments, the Treg cells are FoxP3+ Treg cells. In some embodiments, the Treg cells express CTLA-4, LAG-3, CD25, CD39, CD27, CD70, CD357 (GITR), Neuropilin-1, Galectin-1, and / or IL-2Rα on their surface. In some embodiments, the cells that contain or have been engineered to contain any one of the cell signaling receptors described herein are further engineered to stably express or overexpress FoxP3 (as described in WO18080541), membrane-bound IL10 (e.g., as described in WO2019180724), or a CAR or TCR. WO18080541 and WO2019180724 are incorporated herein by reference in their entirety.

[0099] In some embodiments, the cells are autologous cells. In some embodiments, the cells are allogeneic cells. In some embodiments, the cell comprising the chimeric signaling receptor or a nucleic acid encoding a chimeric signaling receptor further comprises or expresses a TCR or a CAR.

[0100] Stabilized FoxP3 expression Some embodiments of the methods of modifying cells described herein include introducing a genetic modification into the cell that stabilizes the expression of FoxP3. Similarly, some embodiments of the cells described herein include a genetic modification that stabilizes or increases FoxP3 expression compared to unmodified cells. Furthermore, some embodiments of the nucleic acids and vectors described herein stabilize FoxP3 expression in cells.

[0101] In some embodiments, the endogenous FOXP3 locus in cells is modified to obtain stable expression. For example, in some embodiments, a heterologous promoter is inserted into or downstream of a Treg-specific demethylation region (TSDR) in the genome and upstream of the first coding exon of the endogenous FOXP3 coding sequence. In some embodiments, the promoter is inserted downstream of the TSDR and into or upstream of the first coding exon of FOXP3. Inserting a heterologous promoter in this manner avoids the endogenous regulation of FOXP3 by the TSDR. The TSDR may be methylated in inflammatory conditions, inhibiting the transcription of the endogenous FOXP3 coding sequence from the endogenous FOXP3 promoter upstream of the TSDR. Thus, such stable FoxP3 expression by heterologous promoter insertion allows stable FoxP3 expression even in inflammatory conditions, preventing transdifferentiation into T effector cells.

[0102] The heterologous promoter can be inserted at any position between the endogenous promoter and the first coding exon of the FOXP3 coding sequence. In some embodiments, the heterologous promoter is inserted 1 to 10,000, 10 to 1,000, 10 to 100, 10 to 5,000, 20 to 4,000, 30 to 3,000, 40 to 2,000, 50 to 1,000, 60 to 750, 70 to 500, 80 to 400, 90 to 300, 100 to 200, 1 to 1,000, 1,000 to 2,000, 2,000 to 3,000, 3,000 to 4,000, 4,000 to 5,000, 5,000 to 6,000, 6,000 to 7,000, 7,000 to 8,000, 8,000 to 9,000, or 9,000 to 10,000 nucleotides downstream from the TSDR of FOXP3. In some embodiments, the heterologous promoter is 1-10,000, 10-1,000, 10-100, 10-5,000, 20-4,000, 30-3,000, 40-2,000, 50-1,000, 60-750, 70-500, 80-400, 90-300, 100-1000, 100-2000, 100-3000, 100-400, 100-500, 100-600, 100-700, 100-800, 100-900, 100-1000, 100-1000, 100-2000, 100-3000, 100-400, 1 The heterologous promoter is inserted 0, 100-200, 1-1,000, 1,000-2,000, 2,000-3,000, 3,000-4,000, 4,000-5,000, 5,000-6,000, 6,000-7,000, 7,000-8,000, 8,000-9,000, or 9,000-10,000 nucleotides upstream. In some embodiments, a heterologous promoter is inserted into the first coding exon to create a synthetic first coding exon. The synthetic first coding exon is distinct from the endogenous first coding exon but still contains an initiation codon that is in frame with the FOXP3 coding sequence of the downstream FOXP3 exon. In some embodiments, a heterologous promoter is inserted into the TSDR such that the TSDR is modified so that it does not inhibit transcription of the endogenous FOXP3 coding sequence in inflammatory conditions.

[0103] In some embodiments, the nucleic acid comprising the heterologous promoter is included in a vector. In some embodiments, the vector is a viral vector. In some embodiments, the viral vector is an adeno-associated viral (AAV) vector. In some embodiments, the AAV vector is an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, or AAV11 vector. In some embodiments, the AAV vector is an AAV5 vector. In some embodiments, the AAV vector is an AAV6 vector.

[0104] In some embodiments, a nucleic acid comprising a promoter operably linked to a nucleic acid sequence encoding FoxP3 or a functional derivative thereof is introduced into a cell. The expression of a heterologous promoter and a sequence encoding FoxP3 is useful, for example, to express functional FoxP3 in a cell that contains a genomic mutation in the FOXP3 coding sequence (e.g., a cell of a subject with IPEX syndrome). Additionally, additional coding sequences (e.g., encoding a chimeric signaling receptor as described herein) may be included in the nucleic acid, such that the heterologous promoter controls the transcription of an RNA encoding the FoxP3 sequence and one or more other proteins (e.g., a chimeric signaling receptor). In some embodiments, the sequence encoding FoxP3 is an intron-free cDNA sequence.

[0105] The introduced nucleic acid may be integrated (e.g., by homologous recombination), integrated in a non-targeted manner (e.g., by delivery in a lentiviral vector), or not integrated at all into the genome of the target locus. In some embodiments, the nucleic acid comprises a 5' homology arm upstream from a promoter and a 3' homology arm downstream from a nucleic acid sequence encoding FoxP3, both homology arms having homology to the target locus in the genome. Such homology arms facilitate insertion of the nucleic acid into the genome of the target locus by homologous recombination. The homology arms may be the same length, may have similar lengths (within 100 bp of each other), or may differ in length. In some embodiments, one or both homology arms have a length of 200-2,000 bp, 400-1,500 bp, 500-1,000 bp. In some embodiments, one or both homology arms are about 100 bp, about 200 bp, about 300 bp, about 400 bp, about 500 bp, about 600 bp, about 700 bp, about 800 bp, about 900 bp, about 1,000 bp, about 1,100 bp, about 1,200 bp, about 1,300 bp, about 1,400 bp, about 1,500 bp, about 1,600 bp, about 1,700 bp, about 1,800 bp, about 1,900 bp, or about 2,000 bp.

[0106] In some embodiments, the nucleic acid is integrated into the FOXP3 locus in the genome. In some embodiments, the nucleic acid is integrated into a non-FOXP3 locus. In some embodiments, the target locus is a safe harbor locus. In some embodiments, the safe harbor locus is the AAVS1 locus, the HIPP11 locus, or the ROSA26 locus. In some embodiments, the nucleic acid is integrated into the TCR alpha (TRAC) locus. In some embodiments, the nucleic acid is integrated into the TCR beta (TRBC) locus.

[0107] In some embodiments, a nuclease capable of cleaving the genome at the target locus, or a nucleic acid (e.g., mRNA) encoding the nuclease, is introduced into the cell. Following delivery of the nuclease or transcription of the nuclease in the cell, the nuclease introduces a double-stranded break at the target locus, thereby facilitating integration of the donor template (e.g., a nucleic acid comprising a promoter and a sequence encoding FoxP3, or a nucleic acid comprising a heterologous promoter for facilitating transcription of an endogenous FOXP3 coding sequence) into the genome at the target locus by homologous recombination repair. The nuclease can be any nuclease known in the art, including meganucleases, zinc finger nucleases, TALENs, or RNA-guided nucleases. In embodiments in which an RNA-guided nuclease (or a nucleic acid encoding an RNA-guided nuclease) is delivered, a guide RNA (or a nucleic acid encoding a guide RNA) comprising a spacer sequence complementary to the genomic sequence at the target locus is introduced into the cell. The gRNA or a nucleic acid encoding the gRNA may be introduced into the cell together with the nuclease or a nucleic acid encoding the nuclease, or may be introduced separately (e.g., in a separate vector or delivery vehicle). The RNA-guided nuclease may be any RNA-guided nuclease known in the art or described herein.

[0108] In some embodiments, the vector is a nucleic acid comprising a heterologous promoter operably linked to a sequence encoding FoxP3 or a functional derivative thereof. In some embodiments, the vector is a viral vector. In some embodiments, the vector is a lentiviral vector. In some embodiments, the vector is an adeno-associated virus (AAV) vector. In some embodiments, the AAV vector is an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, or AAV11 vector. In some embodiments, the AAV vector is an AAV5 vector. In some embodiments, the AAV vector is an AAV6 vector. In some embodiments, the vector is a plasmid. In some embodiments, the vector is a bacterial artificial chromosome. In some embodiments, the vector is a human artificial chromosome. In some embodiments, the vector is integrated into a chromosome of the genome and the RNA encoding FoxP3 is transcribed from the genome of the cell. In other embodiments, the vector is not integrated into a chromosome and the sequence encoding FoxP3 is expressed episomally.

[0109] The heterologous promoter inserted into the FOXP3 locus or operably linked to the FOXP3 coding sequence can be any promoter known in the art. In some embodiments, the promoter is a constitutive promoter. In some embodiments, the promoter is an MND, PGK, or EF-1α promoter. In some embodiments, the promoter is an MND promoter. In some embodiments, the promoter is an inducible promoter. In some embodiments, the promoter is inducible by a drug or steroid.

[0110] Antigen-specific receptor polypeptides Some embodiments of the methods for producing engineered cells described herein include introducing into the cell a nucleic acid encoding an antigen-specific receptor (e.g., a T cell receptor (TCR) or chimeric antigen receptor (CAR)) polypeptide, or a portion thereof (e.g., a TCR alpha chain or a TCR beta chain). Similarly, some embodiments of the cells described herein include a nucleic acid encoding an antigen-specific receptor. Additionally, some embodiments of the nucleic acids and vectors described herein (e.g., for in vivo administration) encode a TCR or a CAR, or a portion thereof. In some embodiments, the nucleic acid is inserted into the TRAC locus or the TRBC locus, or includes homology arms to direct insertion into the TRAC locus or the TRBC locus.

[0111] In some embodiments, a nucleic acid is inserted or designed to be inserted into the TRAC or TRBC locus to capture the endogenous promoter. Promoter capture involves introducing an exogenous sequence into the locus such that its expression is driven by the endogenous promoter. For example, a cell can be edited (in vitro or in vivo) by inserting a nucleic acid molecule comprising a nucleic acid encoding an exogenous TCR or CAR or a portion thereof into the TRAC or TRBC locus. In this case, the nucleic acid encoding the TCR or CAR is inserted downstream (e.g., 11-10,000 bp downstream) of the endogenous TRAC or TRBC promoter, such that the endogenous TRAC or TRBC promoter is operably linked to the inserted nucleic acid and drives expression of the exogenous TCR or CAR.

[0112] In some embodiments, the nucleic acid is inserted or designed to be inserted into the TRAC or TRBC locus such that the insertion inhibits expression of the endogenous TCR alpha or TCR beta chain. In some embodiments, the coding sequence, or a portion of the coding sequence, of the endogenous TCR alpha or TCR beta chain is removed from the locus such that endogenous TCR alpha or TCR beta is not expressed in the cell. In some embodiments, the inserted nucleic acid comprises a heterologous promoter that drives expression of the inserted TCR or CAR.

[0113] In some embodiments, a nucleic acid is inserted or designed to be inserted into the TRAC or TRBC locus to hijack the endogenous TRAC or TRBC gene by a heterologous promoter. For example, a cell can be edited by inserting a polynucleotide molecule comprising (a) a promoter operably linked to a nucleic acid encoding a full-length TCRβ protein and a nucleic acid encoding a TCRα variable (TRAV) region and a TCR binding (TRAJ) region. Here, the coding sequence for the TRAV and TRAJ regions is inserted in frame with the coding sequence encoding the TCRα constant region, such that the inserted heterologous promoter controls the transcription of the heterologous TCRβ protein, as well as the transcription of the TCRα protein comprising the heterologous TRAV / TRAJ amino acid sequence and the endogenous TCRα constant region amino acid sequence. This embodiment utilizes the endogenous 3' regulatory region from the endogenous TRAC gene. A similar approach can also be used to hijack the endogenous TRBC locus. In this case, the full-length protein encoded is a TCRα chain, and the nucleic acid further encodes the TCRβ variable region and the TCRβ binding region in frame with the TCRβ constant region.

[0114] In some embodiments, the antigen-specific receptor is episomally expressed in the cell. Episomal expression can be achieved by any method known in the art, such as delivery of RNA (e.g., mRNA or self-amplifying RNA) or DNA (e.g., plasmids or artificial chromosomes) encoding the antigen-specific receptor.

[0115] In embodiments using a heterologous promoter to express the TCR, CAR, or a portion thereof, the heterologous promoter can be any promoter known in the art. In some embodiments, the heterologous promoter is a constitutive promoter. In some embodiments, the promoter is an MND promoter.

[0116] Pharmaceutical Compositions Some aspects of the present disclosure relate to pharmaceutical compositions comprising the cells, vectors, or nucleic acids described herein and a pharma- ceutically acceptable excipient or carrier. Such pharmaceutical compositions are formulated, for example, for systemic administration or for administration to a target tissue. By "acceptable" it is meant that the excipient (carrier) is compatible with (and preferably capable of stabilizing) the active ingredient of the composition and is not harmful to the subject being treated. Pharmaceutically acceptable excipients, carriers, buffers, stabilizers, tonicity agents, preservatives, antioxidants, or other substances well known to those skilled in the art. Such substances should be non-toxic and not interfere with the efficacy of the active ingredient. The exact nature of the carrier or other substance may vary depending on the route of administration (e.g., parenteral, intramuscular, intradermal, sublingual, buccal, ocular, intranasal, subcutaneous, intrathecal, intratumoral, oral, vaginal, or rectal). See, e.g., Remington: The Science and Practice of Pharmacy 20th Ed. (2000) Lippincott Williams and Wilkins, Ed. K.E. Hoover. Pharmaceutical compositions used for in vivo administration must be sterile, except for the cells, viruses, and / or viral vectors used to achieve a biological effect (such as immunosuppression). This is readily accomplished, for example, by filtration through sterile filtration membranes. The pharmaceutical compositions described herein may be placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper that can be pierced by a hypodermic injection needle.

[0117] In some embodiments, the pharmaceutical compositions described herein can be formulated for intramuscular, intravenous, intradermal, or subcutaneous injection. The pharmaceutical compositions described herein for use in the methods of the invention may include pharma- ceutically acceptable carriers, buffers, excipients, salts, or stabilizers in the form of lyophilized formulations or aqueous solutions. See, e.g., Remington: The Science and Practice of Pharmacy 20th Ed. (2000) Lippincott Williams and Wilkins, Ed. K.E. Hoover. Acceptable carriers, excipients, or stabilizers are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citric acid, and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzylammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl, or benzyl alcohol; alkyl parabens, such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; serum albumin, gelatin, and the like. The surfactants may include proteins such as amino acids, such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextran; chelating agents, such as EDTA; sugars, such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions, such as sodium; metal complexes (e.g., zinc protein complexes); and / or non-ionic surfactants, such as TWEEN®, PLURONIC®, or polyethylene glycol (PEG).

[0118] In some embodiments, the pharmaceutical compositions described herein comprise lipid nanoparticles that can be prepared by methods known in the art, such as those described in Epstein et al., Proc Natl Acad Sci USA. 1985.82:3688; Hwang et al. Proc Natl Acad Sci USA. 1980.77:4030; and U.S. Patent Nos. 4,485,045 and 4,544,545. Liposomes with extended circulation time are disclosed in U.S. Patent No. 5,013,556. Particularly useful liposomes can be produced by reverse phase evaporation using a lipid composition that includes phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to produce liposomes of the desired diameter. Lipids used in the formulation of lipid nanoparticles for delivery of nucleic acids are widely known in the art and include ionizable amino lipids, non-cationic lipids, sterols, and polyethylene glycol-modified lipids. See, e.g., Buschmann et al., Vaccines. 2021.9(1):65. In some embodiments, the nucleic acid is surrounded by the lipids of the lipid nanoparticle and is present inside the lipid nanoparticle. In some embodiments, the nucleic acid is dispersed throughout the lipids of the lipid nanoparticle. In some embodiments, the lipid nanoparticle comprises an ionizable amino lipid, a non-cationic lipid, a sterol, and / or a polyethylene glycol (PEG)-modified lipid.

[0119] The pharmaceutical compositions described herein may be in unit dosage form such as tablets, pills, capsules, powders, granules, solutions or suspensions, or suppositories for oral, parenteral, or rectal administration, or by inhalation or insufflation.

[0120] To prepare solid compositions such as tablets, the principal active ingredient can be mixed with pharmaceutical carriers, e.g., conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate, or gums, and other pharmaceutical diluents such as water, to form a solid preformulation composition containing a homogenous mixture of the compound of the present invention, or a non-toxic pharmaceutically acceptable salt thereof. When these preformulation compositions are referred to as homogenous, this means that the active ingredient is evenly dispersed throughout the composition, and that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills, capsules, and the like. This solid preformulation composition is then divided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the novel compositions can be coated or otherwise compounded to provide a dosage form offering the advantage of sustained action. For example, the tablets or pills can include an inner dosage component and an outer dosage component, the latter being in the form of an envelope over the former. The two components are separated by an enteric layer which resists disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, cellulose acetate, and such other materials.

[0121] Pharmaceutical compositions for inhalation or insufflation include solutions and suspensions in pharma- ceutically acceptable aqueous or organic solvents, or mixtures thereof, as well as powders. The liquid or solid compositions may contain suitable pharma- ceutically acceptable excipients as described above. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect.

[0122] Compositions, preferably in sterile, pharma- ceutically acceptable solvents, may be nebulized by the use of gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a face mask, tent or intermittent positive pressure breathing machine. Solution, suspension or powder compositions may be administered, preferably orally or nasally, from devices which deliver the formulation in an appropriate manner.

[0123] The pharmaceutical compositions described herein may be useful for treating subjects having or at risk of developing an inflammatory, autoimmune, or allergic condition or disease. Subjects having or at risk of developing an inflammatory, autoimmune, or allergic condition or disease can be identified by determining the presence or absence of one or more risk factors, diagnostic indicators, or prognostic indicators. This determination can be made based on clinical, cellular, or serological findings, including flow cytometry, serology, and / or DNA analysis, as known in the art.

[0124] The pharmaceutical compositions described herein can include a therapeutically effective amount of any of the cells, vectors, and / or nucleic acids described herein. For example, in some embodiments, the pharmaceutical compositions include any dose of the cells, vectors, or nucleic acids described herein.

[0125] A "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result. A therapeutically effective amount may vary depending on factors such as the age, sex, weight of the individual, and the ability of the cells, nucleic acids, or vectors to produce a desired response in a subject.

[0126] Pharmaceutical compositions can be prepared according to known techniques. For example, see Remington, The Science And Practice of Pharmacy (21st ed., Philadelphia, Lippincott, Williams & Wilkins, 2005). For example, the cells, vectors, or nucleic acids described herein are mixed with pharma- ceutically acceptable excipients, and the resulting composition is administered to a subject. The carrier must be acceptable in the sense of being compatible with other ingredients in the formulation and not deleterious to the subject. The carrier can be solid, liquid, or both, and can be formulated with the compound as a unit dose formulation.

[0127] In some embodiments, the pharmaceutical composition comprises about 10 4 ~about 10 10 In some embodiments, the pharmaceutical composition comprises a dose of about 10 4 ~10 5 , 10 5 ~10 6 , 10 6 ~10 7 , 10 7 ~10 8 , 10 8 ~10 9 , or 10 9 ~10 10 In some embodiments, the pharmaceutical composition comprises a dose of about 0.1×10 cells / kg of cells. 6 , 0.2×10 6 , 0.3×10 6 , 0.4×10 6 , 0.5×10 6 , 0.6×10 6 , 0.7×10 6 , 0.8×10 6 , 0.9×10 6 , 1.0×10 6 , 1.1×10 6 , 1.2×10 6 , 1.3×10 6 , 1.4×10 6 , 1.5×10 6 , 1.6×10 6 , 1.7×10 6、1.8×10 6 、1.9×10 6 、2.0×10 6 、2.1×10 6 、2.2×10 6 、2.3×10 6 、2.4×10 6 、2.5×10 6 、2.6×10 6 、2.7×10 6 、2.8×10 6 、2.9×10 6 、3.0×10 6 、3.1×10 6 、3.2×10 6 、3.3×10 6 、3.4×10 6 、3.5×10 6 、3.6×10 6 、3.7×10 6 、3.8×10 6 、3.9×10 6 、4.0×10 6 、4.1×10 6 、4.2×10 6 、4.3×10 6 、4.4×10 6 、4.5×10 6 、4.6×10 6 、4.7×10 6 、4.8×10 6 、4.9×10 6 、5.0×10 6 、5.1×10 6 、5.2×10 6 、5.3×10 6 、5.4×10 6 、5.5×10 6 、5.6×10 6 、5.7×10 6 、5.8×10 6 、5.9×10 6 、6.0×10 6 、6.1×10 6 、6.2×10 6 、6.3×10 6 、6.4×10 6 、6.5×10 6 、6.6×10 6 、6.7×10 6、6.8×10 6 、6.9×10 6 、7.0×10 6 、7.1×10 6 、7.2×10 6 、7.3×10 6 、7.4×10 6 、7.5×10 6 、7.6×10 6 、7.7×10 6 、7.8×10 6 、7.9×10 6 、8.0×10 6 、8.1×10 6 、8.2×10 6 、8.3×10 6 、8.4×10 6 、8.5×10 6 、8.6×10 6 、8.7×10 6 、8.8×10 6 、8.9×10 6 、9.0×10 6 、9.1×10 6 、9.2×10 6 、9.3×10 6 、9.4×10 6 、9.5×10 6 、9.6×10 6 、9.7×10 6 、9.8×10 6 、9.9×10 6 、1.0×10 7 、1.1×10 7 、1.2×10 7 、1.3×10 7 、1.4×10 7 、1.5×10 7 、1.6×10 7 、1.7×10 7 、1.8×10 7 、1.9×10 7 、2.0×10 7 、2.1×10 7 、2.2×10 7 、2.3×10 7 、2.4×10 7 、2.5×10 7 、2.6×10 7 、2.7×10 7、2.8×10 7 、2.9×10 7 、3.0×10 7 、3.1×10 7 、3.2×10 7 、3.3×10 7 、3.4×10 7 、3.5×10 7 、3.6×10 7 、3.7×10 7 、3.8×10 7 、3.9×10 7 、4.0×10 7 、4.1×10 7 、4.2×10 7 、4.3×10 7 、4.4×10 7 、4.5×10 7 、4.6×10 7 、4.7×10 7 、4.8×10 7 、4.9×10 7 、5.0×10 7 、5.1×10 7 、5.2×10 7 、5.3×10 7 、5.4×10 7 、5.5×10 7 、5.6×10 7 、5.7×10 7 、5.8×10 7 、5.9×10 7 、6.0×10 7 、6.1×10 7 、6.2×10 7 、6.3×10 7 、6.4×10 7 、6.5×10 7 、6.6×10 7 、6.7×10 7 、6.8×10 7 、6.9×10 7 、7.0×10 7 、7.1×10 7 、7.2×10 7 、7.3×10 7 、7.4×10 7 、7.5×10 7 、7.6×10 7 、7.7×10 7, 7.8×10 7 , 7.9×10 7 , 8.0×10 7 , 8.1×10 7 , 8.2×10 7 , 8.3×10 7 , 8.4×10 7 , 8.5×10 7 , 8.6×10 7 , 8.7×10 7 , 8.8×10 7 , 8.9×10 7 , 9.0×10 7 , 9.1×10 7 , 9.2×10 7 , 9.3×10 7 , 9.4×10 7 , 9.5×10 7 , 9.6×10 7 , 9.7×10 7 , 9.8×10 7 , 9.9×10 7 , or 1.0×10 8 Cells are included at a dose of cells / kg.

[0128] In some embodiments, the pharmaceutical composition comprises an effective amount of a vector or nucleic acid described herein. In some examples, the pharmaceutical composition comprises about 0.1 mg / kg to about 3 mg / kg of the vector or nucleic acid. In some embodiments, the pharmaceutical composition comprises about 0.1 mg / kg, about 0.25 mg / kg, about 0.5 mg / kg, about 0.75 mg / kg, about 1.0 mg / kg, about 1.5 mg / kg, about 2.0 mg / kg, about 2.5 mg / kg, or about 3.0 mg / kg of the vector or nucleic acid. In some embodiments, the pharmaceutical composition comprises about 0.1 mg / kg to about 0.25 mg / kg, about 0.25 mg / kg to about 0.5 mg / kg, about 0.5 mg / kg to about 0.75 mg / kg, about 0.75 mg / kg to about 1.0 mg / kg, about 1.0 mg / kg to about 1.5 mg / kg, about 1.5 mg / kg to about 2.0 mg / kg, about 2.0 mg / kg to about 2.5 mg / kg, or about 2.5 mg / kg to about 3.0 mg / kg of the vector or nucleic acid.

[0129] In some embodiments, the pharmaceutical composition comprises a vector or nucleic acid encapsulated within a lipid nanoparticle. Some embodiments of lipid nanoparticles include at least one cationic lipid, at least one non-cationic lipid, and at least one conjugate lipid. In a more specific example, the lipid nanoparticles are generated to have a non-lamellar (i.e., non-bilayer) morphology, including about 50 mol% to about 85 mol% cationic lipid, about 13 mol% to about 49.5 mol% non-cationic lipid, and about 0.5 mol% to about 10 mol% lipid complex. In another specific example, the lipid nanoparticles are generated to have a non-lamellar (i.e., non-bilayer) morphology, including about 40 mol% to about 85 mol% cationic lipid, about 13 mol% to about 49.5 mol% non-cationic lipid, and about 0.5 mol% to about 10 mol% lipid complex.

[0130] Cationic lipids include, for example, one or more of the following: palmitoyloleoylnorarginine (PONA), MPDACA, GUADACA, ((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate) (MC3), LenMC3, CP-LenMC3, γ-LenMC3, CP-γ-LenMC3, MC3MC, MC2MC, MC3 ether, MC4 ether, MC3 amide, Pan-MC3, Pan-MC4, and Pan-MC5, 1,2-diaminophenyl ether ... Noreyoxy-N,N-dimethylaminopropane (DLinDMA), 1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), 2,2-Dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-K-C2-DMA; "XTC2"), 2,2-Dilinoleyl-4-(3-dimethylaminopropyl)-[1,3]-dioxolane (DLin-K-C3-DMA), 2,2-Dilinoleyl-4-(4-dimethylaminobutyl)-[1,3]-dioxolane (DLin-K-C4-DMA). A), 2,2-Dilinoleyl-5-dimethylaminomethyl-[1,3]-dioxane (DLin-K6-DMA), 2,2-Dilinoleyl-4-N-methylpepiazino-[1,3]-dioxolane (DLin-K-MPZ), 2,2-Dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA), 1,2-Dilinoleylcarbamoyloxy-3-dimethylaminopropane (DLin-C-DAP), 1,2-Dilinoleyloxy-3-(dimethylamino)acetoxypropane (DLin-DAC), 1,2 -Dilinoleyloxy-3-morpholinopropane (DLin-MA), 1,2-Dilinoleoyl-3-dimethylaminopropane (DLinDAP), 1,2-Dilinoleylthio-3-dimethylaminopropane (DLin-S-DMA), 1-Linoleoyl-2-linoleyloxy-3-dimethylaminopropane (DLin-2-DMAP), 1,2-Dilinoleyloxy-3-trimethylaminopropane chloride salt (DLin-TMA.Cl), 1,2-Dilinoleoyl-3-trimethylaminopropane chloride salt (DLin-TAP.Cl), 1,2-Dilinoleyloxy-3-(N-methylpiperazino)propane (DLin-MPZ), 3-(N,N-Dilinoleylamino)-1,2-propanediol (DLinAP), 3-(N,N-Dioleylamino)-1,2-propanediol (DOAP), 1,2-Dilinoleyloxo-3-(2-N,N-dimethylamino)ethoxypropane (DLin-EG-DMA), N,N-Dioleyl-N,N-dimethylammonium chloride (DODAC), 1,2-Dioleyloxy-N,N-dimethyl Aminopropane (DODMA), 1,2-distearyloxy-N,N-dimethylaminopropane (DSDMA), N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP), 3-(N-(N',N'-dimethylaminoethane)-carba moyl)cholesterol (DC-Chol), N-(1,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethylammonium bromide (DMRIE), 2,3-dioleyloxy-N-[2(spermine-carboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA), dioctadecylamidoglycylspermine (DOGS), 3-dimethylamino-2-(cholest-5-ene-3-beta-oxybutane-4-yl)-4-methyl-2-propanediol (DMDI), 1,2-diamino-2-(cholest-5-ene-3-beta-oxybutanediol ... -oxy)-1-(cis,cis-9,12-octadecadienoxy)propane (CLinDMA), 2-[5'-(cholest-5-ene-3-beta-oxy)-3'-oxapentoxy)-3-dimethyl-1-(cis,cis-9',1-2'-octadecadienoxy)propane (CpLinDMA), N,N-dimethyl-3,4-dioleyloxybenzylamine (DMOBA), 1,2-N,N'-dioleylcarbamyl-3-dimethylaminopropane (DOcarbDAP), 1,2-N,N'-Dilinoleylcarbamyl-3-dimethylaminopropane (DLincarbDAP), or mixtures thereof. The cationic lipid may be DLinDMA, DLin-K-C2-DMA ("XTC2"), MC3, LenMC3, CP-LenMC3, γ-LenMC3, CP-γ-LenMC3, MC3MC, MC2MC, MC3 ether, MC4 ether, MC3 amide, Pan-MC3, Pan-MC4, PanMC5, or mixtures thereof.

[0131] In various embodiments, the cationic lipid may comprise from about 50 mol% to about 90 mol%, from about 50 mol% to about 85 mol%, from about 50 mol% to about 80 mol%, from about 50 mol% to about 75 mol%, from about 50 mol% to about 70 mol%, from about 50 mol% to about 65 mol%, or from about 50 mol% to about 60 mol% of the total lipid present in the particle.

[0132] In other embodiments, the cationic lipid may comprise from about 40 mol% to about 90 mol%, from about 40 mol% to about 85 mol%, from about 40 mol% to about 80 mol%, from about 40 mol% to about 75 mol%, from about 40 mol% to about 70 mol%, from about 40 mol% to about 65 mol%, or from about 40 mol% to about 60 mol% of the total lipid present in the particle.

[0133] Non-cationic lipids can include, for example, one or more anionic lipids and / or neutral lipids.In certain embodiments, non-cationic lipids include one of the following neutral lipid components: (1) cholesterol or its derivatives, (2) phospholipids, or (3) a mixture of phospholipids and cholesterol or its derivatives.Examples of cholesterol derivatives include, but are not limited to, cholestanol, cholestanone, cholestenone, coprostanol, cholesteryl-2'-hydroxyethyl ether, cholesteryl-4'-hydroxybutyl ether, and mixtures thereof. The phospholipid may be a neutral lipid, including, but not limited to, dipalmitoyl phosphatidylcholine (DPPC), distearoyl phosphatidylcholine (DSPC), dioleoyl phosphatidylethanolamine (DOPE), palmitoyl oleoyl phosphatidylcholine (POPC), palmitoyl oleoyl phosphatidylethanolamine (POPE), palmitoyl oleoyl phosphatidylglycerol (POPG), dipalmitoyl phosphatidylethanolamine (DPPE), dimyristoyl phosphatidylethanolamine (DMPE), distearoyl phosphatidylethanolamine (DSPE), monomethyl phosphatidylethanolamine, dimethyl phosphatidylethanolamine, dielaidoyl phosphatidylethanolamine (DEPE), stearoyl oleoyl phosphatidylethanolamine (SOPE), egg phosphatidylcholine (EPC), and mixtures thereof. In certain embodiments, the phospholipid is DPPC, DSPC, or a mixture thereof.

[0134] In some embodiments, the non-cationic lipid (e.g., one or more phospholipids and / or cholesterol) may comprise about 10 mol% to about 60 mol%, about 15 mol% to about 60 mol%, about 20 mol% to about 60 mol%, about 25 mol% to about 60 mol%, about 30 mol% to about 60 mol%, about 10 mol% to about 55 mol%, about 15 mol% to about 55 mol%, about 20 mol% to about 55 mol%, about 25 mol% to about 55 mol%, about 30 mol% to about 55 mol%, about 13 mol% to about 50 mol%, about 15 mol% to about 50 mol%, or about 20 mol% to about 50 mol% of the total lipid present in the particle. When the non-cationic lipid is a mixture of phospholipid and cholesterol or cholesterol derivative, the mixture may comprise up to about 40, 50, or 60 mol% of the total lipid present in the particle.

[0135] The conjugate lipid that inhibits particle aggregation can include, for example, one or more of polyethylene glycol (PEG)-lipid conjugates, polyamide (ATTA)-lipid conjugates, cationic polymer-lipid conjugates (CPL), or mixtures thereof. In certain embodiments, the nucleic acid-lipid particles include either PEG-lipid conjugates or ATTA-lipid conjugates. In certain embodiments, the PEG-lipid conjugates or ATTA-lipid conjugates are used together with CPL. The conjugate lipid that inhibits particle aggregation can include, for example, PEG-lipids including PEG-diacylglycerol (DAG), PEG dialkyloxypropyl (DAA), PEG-phospholipids, PEG-ceramide (Cer), or mixtures thereof. The PEG-DAA conjugate can be PEG-dilauryloxypropyl (C12), PEG-dimyristyloxypropyl (C14), PEG-dipalmityloxypropyl (C16), PEG-distearyloxypropyl (C18), or mixtures thereof.

[0136] Additional PEG-lipid conjugates suitable for use in the present invention include, but are not limited to, mPEG2000-1,2-di-O-alkyl-sn3-carbomoyl glycerides (PEG-C-DOMG). The synthesis of PEG-C-DOMG is described in PCT Application No. PCT / US08 / 88676. Additional PEG-lipid conjugates suitable for use in the present invention include, but are not limited to, 1-[8'-(1,2-dimyristoyl-3-propanoxy)-carboxamido-3',6'-dioxaoctanyl]carbamoyl-ω-methyl-poly(ethylene glycol) (2KPEG-DMG). The synthesis of 2KPEG-DMG is described in U.S. Patent No. 7,404,969.

[0137] In some cases, the conjugate lipid (e.g., PEG-lipid conjugate) that inhibits particle aggregation may comprise about 0.1 mol% to about 2 mol%, about 0.5 mol% to about 2 mol%, about 1 mol% to about 2 mol%, about 0.6 mol% to about 1.9 mol%, about 0.7 mol% to about 1.8 mol%, about 0.8 mol% to about 1.7 mol%, about 1 mol% to about 1.8 mol%, about 1.2 mol% to about 1.8 mol%, about 1.2 mol% to about 1.7 mol%, about 1.3 mol% to about 1.6 mol%, about 1.4 mol% to about 1.5 mol%, or about 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or 2 mol% (or any percentage or range therein) of the total lipid present in the particle. Typically, in such cases, the average molecular weight of the PEG moiety is about 2,000 Daltons. In other cases, the conjugate lipid (e.g., PEG-lipid conjugate) that inhibits particle aggregation may comprise about 5.0 mol% to about 10 mol%, about 5 mol% to about 9 mol%, about 5 mol% to about 8 mol%, about 6 mol% to about 9 mol%, about 6 mol% to about 8 mol%, or about 5 mol%, 6 mol%, 7 mol%, 8 mol%, 9 mol%, or 10 mol% (or any percentage or range therein) of the total lipid present in the particle. Typically, in such cases, the average molecular weight of the PEG moiety is about 750 Daltons.

[0138] In another embodiment, the composition may comprise amphoteric liposomes comprising at least one positive charge carrier and at least one negative charge carrier different from the positive charge carrier, the isoelectric point of the liposomes being between 4 and 8. This objective is achieved by the fact that the liposomes are prepared with a charge that varies in a pH-dependent manner.

[0139] Liposomal structures with desirable properties are formed, for example, when the amount of membrane-forming or membrane-based cationic charge carriers exceeds the amount of anionic charge carriers at low pH and the ratio is reversed at high pH. This is always the case when the pKa values ​​of the ionizable components are between 4 and 9. As the pH of the medium decreases, all cationic charge carriers become more charged and all anionic charge carriers lose their charge.

[0140] Cationic compounds useful for amphoteric liposomes include the cationic compounds described herein above.Non-limiting examples of strong cationic compounds include DC-Chol3-β-[N-(N',N'-dimethylmethane)carbamoyl]cholesterol, TC-Chol3-β-[N-(N',N',N'-trimethylaminoethane)carbamoylcholesterol, BGSC bisguanidinium spermidine cholesterol, BGTC bisguanidinium-tren-cholesterol, DOTAP(1,2-dioleoyloxypropyl)-N,N,N-trimethylammonium chloride, DOSPER(1,3-dioleoyloxy-2-(6-carboxy-spermyl)-propylamide, DOTMA(1,2-dioleoyloxypropyl)-N,N,N-trimethylammonium chloride) (Lipofectin™), DORIE ... 1,2-dioleoyloxypropyl)-3-dimethylhydroxyethylammonium bromide, DOSC (1,2-dioleoyl-3-succinyl-sn-glyceryl choline ester), DOGSDSO (1,2-dioleoyl-sn-glycero-3-succinyl-2-hydroxyethyl disulfide ornithine), DDAB dimethyldioctadecylammonium bromide, DOGS ((C18)2GlySper3+) N,N-dioctadecylamido-glycol-spermine (Transfectam™) (C18)2Gly+N,N-dioctadecylamido-glycine, CTAB cetyltrimethylammonium bromide, CpyC cetylpyridinium chloride, DOEPC 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine or other O-alkyl-phosphatidylcholines or ethanolamines, amides from lysine, arginine or ornithine, and phosphatidylethanolamine.

[0141] Examples of weakly cationic compounds include, but are not limited to, His-Chol (histaminyl cholesterol hemisuccinate), Mo-Chol (morpholine-N-ethylamino cholesterol hemisuccinate), or histidinyl-PE.

[0142] Examples of neutral compounds include, but are not limited to, cholesterol, ceramide, phosphatidylcholine, phosphatidylethanolamine, tetraether lipids, or diacylglycerol.

[0143] Anionic compounds useful for amphoteric liposomes include the non-cationic compounds previously described herein. Non-limiting examples of weakly anionic compounds include CHEMS (cholesterol hemisuccinate), alkyl carboxylic acids containing 8-25 carbon atoms, or diacylglycerol hemisuccinate. Further weakly anionic compounds include amides of aspartic acid or glutamic acid with PE, and amides of PS with glycine, alanine, glutamine, asparagine, serine, cysteine, threonine, tyrosine, glutamic acid, aspartic acid, or other amino acids or aminodicarboxylic acids. Following the same principle, esters of hydroxycarboxylic acids or hydroxydicarboxylic acids with PS are also weakly anionic compounds.

[0144] In some embodiments, amphoteric liposomes may contain conjugated lipids, such as those described herein above.Specific examples of useful conjugated lipids include, but are not limited to, PEG-modified phosphatidylethanolamines and phosphatidic acids, PEG-ceramide conjugates (e.g., PEG-CerC14 or PEG-CerC20), PEG-modified dialkylamines, and PEG-modified 1,2-diacyloxypropan-3-amines.Specific examples are PEG-modified diacylglycerols and dialkylglycerols.

[0145] In some embodiments, the neutral lipids may comprise about 10 mol% to about 60 mol%, about 15 mol% to about 60 mol%, about 20 mol% to about 60 mol%, about 25 mol% to about 60 mol%, about 30 mol% to about 60 mol%, about 10 mol% to about 55 mol%, about 15 mol% to about 55 mol%, about 20 mol% to about 55 mol%, about 25 mol% to about 55 mol%, about 30 mol% to about 55 mol%, about 13 mol% to about 50 mol%, about 15 mol% to about 50 mol%, or about 20 mol% to about 50 mol% of the total lipids present in the particle.

[0146] In some cases, the conjugate lipid (e.g., PEG-lipid conjugate) that inhibits particle aggregation may comprise about 0.1 mol% to about 2 mol%, about 0.5 mol% to about 2 mol%, about 1 mol% to about 2 mol%, about 0.6 mol% to about 1.9 mol%, about 0.7 mol% to about 1.8 mol%, about 0.8 mol% to about 1.7 mol%, about 1 mol% to about 1.8 mol%, about 1.2 mol% to about 1.8 mol%, about 1.2 mol% to about 1.7 mol%, about 1.3 mol% to about 1.6 mol%, about 1.4 mol% to about 1.5 mol%, or about 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or 2 mol% (or any percentage or range therein) of the total lipid present in the particle. Typically, in such cases, the average molecular weight of the PEG moiety is about 2,000 Daltons. In other cases, the conjugate lipid (e.g., PEG-lipid conjugate) that inhibits particle aggregation may comprise about 5.0 mol% to about 10 mol%, about 5 mol% to about 9 mol%, about 5 mol% to about 8 mol%, about 6 mol% to about 9 mol%, about 6 mol% to about 8 mol%, or about 5 mol%, 6 mol%, 7 mol%, 8 mol%, 9 mol%, or 10 mol% (or any percentage or range therein) of the total lipid present in the particle. Typically, in such cases, the average molecular weight of the PEG moiety is about 750 Daltons.

[0147] Considering the total amount of neutral lipids and conjugate lipids, the remaining balance of the amphoteric liposome can be made up of a mixture of cationic and anionic compounds formulated in various ratios. The ratio of cationic to anionic lipids can be selected to achieve the desired properties of nucleic acid encapsulation, Zeta potential, pKa, or other physicochemical properties that depend at least in part on the presence of charged lipid components.

[0148] In some embodiments, the lipid nanoparticles have a composition that specifically enhances delivery and uptake to stem cells, hematopoietic cells, or T cells. In some embodiments, the pharmaceutical composition comprises an effective amount of a lipid nanoparticle formulation, the lipid nanoparticle formulation comprising a vector or nucleic acid described herein. In some examples, the lipid nanoparticle formulation comprises about 0.1 mg / kg to about 3 mg / kg of a vector or nucleic acid. In some embodiments, the lipid nanoparticle formulation comprises about 0.1 mg / kg, about 0.25 mg / kg, about 0.5 mg / kg, about 0.75 mg / kg, about 1.0 mg / kg, about 1.5 mg / kg, about 2.0 mg / kg, about 2.5 mg / kg, or about 3.0 mg / kg of a vector or nucleic acid. In some embodiments, the lipid nanoparticle formulation comprises about 0.1 mg / kg to about 0.25 mg / kg, about 0.25 mg / kg to about 0.5 mg / kg, about 0.5 mg / kg to about 0.75 mg / kg, about 0.75 mg / kg to about 1.0 mg / kg, about 1.0 mg / kg to about 1.5 mg / kg, about 1.5 mg / kg to about 2.0 mg / kg, about 2.0 mg / kg to about 2.5 mg / kg, or about 2.5 mg / kg to about 3.0 mg / kg of vector or nucleic acid.

[0149] In some embodiments, the pharmaceutical composition comprises a lipid nanoparticle formulation comprising an effective amount of a donor template comprising a template nucleic acid described herein, the lipid nanoparticle formulation comprising about 0.1 mg / kg to about 3 mg / kg of donor polynucleotide, in some embodiments, the lipid nanoparticle formulation comprises about 0.1 mg / kg, about 0.25 mg / kg, about 0.5 mg / kg, about 0.75 mg / kg, about 1.0 mg / kg, about 1.5 mg / kg, about 2.0 mg / kg, about 2.5 mg / kg, or about 3.0 mg / kg of donor polynucleotide. In some embodiments, the lipid nanoparticle formulation comprises about 0.1 mg / kg to about 0.25 mg / kg, about 0.25 mg / kg to about 0.5 mg / kg, about 0.5 mg / kg to about 0.75 mg / kg, about 0.75 mg / kg to about 1.0 mg / kg, about 1.0 mg / kg to about 1.5 mg / kg, about 1.5 mg / kg to about 2.0 mg / kg, about 2.0 mg / kg to about 2.5 mg / kg, or about 2.5 mg / kg to about 3.0 mg / kg of donor polynucleotide.

[0150] In some embodiments, the pharmaceutical compositions of the invention may further comprise one or more additional agents useful for treating an inflammatory, autoimmune, or allergic condition or disease in a subject.

[0151] How to use Some aspects of the present disclosure relate to a method of administering to a subject a cell, vector, nucleic acid, or lipid nanoparticle described herein. In some embodiments, the method includes administering to a subject any one of the cells described herein. In some embodiments, the method includes administering to a subject cells that have been previously obtained from the subject prior to administration (i.e., the cells are autologous cells). In some embodiments, the method includes (i) isolating cells from the subject, (ii) treating the cells by any method described herein (e.g., gene editing or introduction of a vector), and (iii) administering the treated cells to the same subject. In some embodiments, the method includes administering to a subject cells that have been previously obtained from a subject different from the subject to which the cells are administered (i.e., the cells are allogeneic cells). In some embodiments, the method includes (i) isolating cells from a first subject, (ii) treating the cells by any method described herein (e.g., gene editing or introduction of a vector), and (iii) administering the treated cells to a second subject.

[0152] Some embodiments of the methods, cells, systems, and compositions described herein include any of the cells, vectors, nucleic acids, or lipid nanoparticles described herein for use as a medicament, in some embodiments, the cells, vectors, nucleic acids, or lipid nanoparticles are used in a method to prevent, treat, inhibit, or ameliorate an inflammatory, autoimmune, or allergic condition or disease in a subject.

[0153] In some embodiments, described herein are cells for use in a method of preventing, treating, inhibiting, or ameliorating an inflammatory, autoimmune, or allergic condition or disease in a subject. In some embodiments, the cells are autologous to the subject (i.e., derived from the subject). In other embodiments, the cells are allogeneic to the subject (i.e., derived from a different subject).

[0154] inflammatory diseases In some embodiments, the cells, vectors, nucleic acids, or lipid nanoparticles are used to treat, prevent, cure, inhibit, or ameliorate an inflammatory condition or disease in a subject. In some embodiments, the subject is suffering from or at risk of developing an inflammatory condition or disease. In some embodiments, the inflammatory condition or disease is selected from pancreatic islet cell transplantation, asthma, hepatitis, traumatic brain injury, primary sclerosing cholangitis, primary biliary cholangitis, polymyositis, stroke, Still's disease, acute respiratory distress syndrome (ARDS), uveitis, inflammatory bowel disease (IBD), ulcerative colitis, graft-versus-host disease (GvHD), tolerance induction to transplantation, transplant rejection, and sepsis.

[0155] In some embodiments, the inflammatory condition is associated with islet cell transplantation. In some embodiments, the inflammatory disease is asthma. In some embodiments, the inflammatory disease is hepatitis. In some embodiments, the inflammatory condition is traumatic brain injury. In some embodiments, the inflammatory disease is primary sclerosing cholangitis. In some embodiments, the inflammatory disease is primary biliary cholangitis. In some embodiments, the inflammatory disease is polymyositis. In some embodiments, the inflammatory condition is stroke. In some embodiments, the inflammatory disease is Still's disease. In some embodiments, the inflammatory disease is acute respiratory distress syndrome (ARDS). In some embodiments, the inflammatory disease is uveitis. In some embodiments, the inflammatory disease is inflammatory bowel disease (IBD). In some embodiments, the inflammatory disease is graft versus host disease (GvHD). In some embodiments, the inflammatory condition is induced tolerance to transplantation. In some embodiments, the inflammatory condition is transplant rejection. In some embodiments, the inflammatory disease is sepsis.

[0156] In some embodiments, the cells express an antigen-specific receptor (e.g., a T cell receptor or a chimeric antigen receptor) specific for an antigen associated with an inflammatory condition or disease. autoimmune disease In some embodiments, the cells, vectors, nucleic acids, or lipid nanoparticles are used to treat, prevent, cure, inhibit, or ameliorate an autoimmune condition or disease in a subject. In some embodiments, the subject suffers from or is at risk of developing an autoimmune condition or disease. In some embodiments, the autoimmune condition or disease is selected from type 1 diabetes, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, rheumatoid arthritis, early onset rheumatoid arthritis, ankylosing spondylitis, immune-mediated pregnancy loss, immune-mediated recurrent pregnancy loss, dermatomyositis, psoriatic arthritis, Crohn's disease, inflammatory bowel disease (IBD), ulcerative colitis, bullous pemphigoid, pemphigus vulgaris, autoimmune hepatitis, psoriasis, Sjogren's syndrome, and celiac disease.

[0157] In some embodiments, the autoimmune disease is type 1 diabetes. In some embodiments, the autoimmune disease is multiple sclerosis. In some embodiments, the autoimmune disease is systemic lupus erythematosus. In some embodiments, the autoimmune disease is myasthenia gravis. In some embodiments, the autoimmune disease is rheumatoid arthritis. In some embodiments, the autoimmune disease is early onset rheumatoid arthritis. In some embodiments, the autoimmune disease is ankylosing spondylitis. In some embodiments, the autoimmune disease is immune-mediated pregnancy loss. In some embodiments, the autoimmune disease is immune-mediated recurrent pregnancy loss. In some embodiments, the autoimmune disease is dermatomyositis. In some embodiments, the autoimmune disease is psoriatic arthritis. In some embodiments, the autoimmune disease is Crohn's disease. In some embodiments, the autoimmune disease is inflammatory bowel disease (IBD). In some embodiments, the autoimmune disease is ulcerative colitis. In some embodiments, the autoimmune disease is bullous pemphigoid. In some embodiments, the autoimmune disease is pemphigus vulgaris. In some embodiments, the autoimmune disease is autoimmune hepatitis. In some embodiments, the autoimmune disease is psoriasis. In some embodiments, the autoimmune disease is Sjogren's syndrome. In some embodiments, the autoimmune disease is celiac disease.

[0158] In some embodiments, the cells express an antigen-specific receptor (e.g., a T cell receptor or a chimeric antigen receptor) specific for an antigen associated with an autoimmune disease. Allergic diseases In some embodiments, the cells, vectors, nucleic acids, or lipid nanoparticles are used to treat, prevent, cure, inhibit, or ameliorate an allergic condition or disease in a subject. In some embodiments, the subject suffers from or is at risk of developing an allergic condition or disease. In some embodiments, the allergic condition or disease is selected from allergic asthma, steroid-resistant asthma, atopic dermatitis, celiac disease, pollen allergy, food allergy, drug hypersensitivity, and contact dermatitis. In some embodiments, the allergic disease is allergic asthma. In some embodiments, the allergic disease is steroid-resistant asthma. In some embodiments, the allergic disease is atopic dermatitis. In some embodiments, the allergic disease is celiac disease. In some embodiments, the allergic disease is pollen allergy. In some embodiments, the allergic disease is food allergy. In some embodiments, the allergic disease is drug hypersensitivity. In some embodiments, the allergic disease is contact dermatitis.

[0159] In some embodiments, the cells express an antigen-specific receptor (eg, a T cell receptor or a chimeric antigen receptor) specific for an antigen associated with an allergic disease. Administration In some embodiments, the cells, vectors, nucleic acids, or lipid nanoparticles may be administered for 1-14 days over a 30 day period. In some embodiments, dosages may be provided for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days over a 60 day period. Alternative protocols may be appropriate for individual subjects. An appropriate dosage is an amount of compound that, when administered as described above, can detectably alter or ameliorate symptoms or reduce at least one indicator of autoimmune, allergic, or other inflammatory immune activity in a statistically significant manner by at least 10-50% compared to basal levels (e.g., untreated levels), which can be monitored by measuring certain levels of blood components, such as detectable levels of circulating immune cells and / or other inflammatory cells and / or soluble inflammatory mediators, including proinflammatory cytokines.

[0160] In some embodiments, a rapamycin or rapalog is administered to the subject prior to, together with, and / or after administration of the cells. Administration of a rapamycin or rapalog capable of inducing dimerization of CISC components on the cell surface allows for continued IL2 signaling in the body, promoting survival and proliferation of CISC expressing cells without the undesirable effects caused by IL2 administration, such as activation of other T cells. In some embodiments, the rapamycin or rapalog administered is everolimus, CCI-779, C20-methallylrapamycin, C16-(S)-3-methylindolerapamycin, C16-iRap, C16-(S)-7-methylindolerapamycin, AP21967, C16-(S) butylsulfonamidorapamycin, AP23050, mycophenolate sodium, benidipine hydrochloride, AP1903, and AP23573, or metabolites or derivatives thereof. In some embodiments, the rapamycin or rapalog is administered at a dose of 0.001 mg / kg to 10 mg / kg of the subject's body weight, i.e., 0.001 mg / kg to 10 mg / kg. In some embodiments, the rapamycin or rapalog is administered at a dose of 0.001 mg / kg to 0.01 mg / kg, 0.01 mg / kg to 0.1 mg / kg, 0.1 mg / kg to 1 mg / kg, or 1 mg / kg to 10 mg / kg. In some embodiments, the rapamycin or rapalog is administered as a composition separate from the cells. In some embodiments, the rapamycin or rapalog is administered multiple times. In some embodiments, the rapamycin or rapalog is administered for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days or more. In some embodiments, the rapamycin or rapalog is administered for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 weeks or more. In some embodiments, the subject is a human. In some embodiments, administration of the rapamycin or rapalog results in increased survival of the administered cells compared to a subject not administered the rapamycin or rapalog.In some embodiments, administration of the rapamycin or rapalog increases the frequency of cells circulating in the peripheral blood of the subject compared to a subject not receiving the rapamycin or rapalog.

[0161] Typically, appropriate dosages and treatment regimens provide sufficient amounts of cells, vectors, nucleic acids, or lipid nanoparticles to provide a therapeutic and / or prophylactic effect. Such responses can be monitored by establishing improved clinical outcomes (e.g., increased frequency of remission, complete or partial remission, or extended disease-free survival) in treated subjects compared to untreated subjects. A reduction (e.g., a statistically significant reduction when compared to relevant controls) in pre-existing immune responses to antigens associated with the autoimmune, allergic, or other inflammatory diseases described herein typically correlates with improved clinical outcomes. Such immune responses can typically be assessed using standard leukocyte and / or lymphocyte cell surface markers, or cytokine expression, proliferation, cytotoxicity, or released cytokine assays, which are routinely performed in the art and can be performed using samples obtained from the subject before and after treatment.

[0162] In some embodiments, the subject is a human. In some embodiments, the subject is an animal. In some embodiments, the animal is a research animal. In some embodiments, the animal is a farm animal. In some embodiments, the animal is a rodent. In some embodiments, the rodent is a mouse, rat, guinea pig, chinchilla, or hamster. In some embodiments, the animal is a dog, cat, rabbit, guinea pig, hamster, or ferret. In some embodiments, the animal is a cow, pig, llama, alpaca, sheep, or goat.

[0163] Working Example Example 1: Evaluation of cell signaling activities regulated by chimeric signaling receptors 9A-9H show non-limiting examples of chimeric signaling receptors described herein.

[0164] The chimeric signaling receptors containing combinations of the first and second polypeptides were expressed in cells and their activity was evaluated. Cells expressing the chimeric signaling receptors having the [mm]CISC2RsL FRB and [mm]CISC2ReL FKBP polypeptides, the RISE10RhL FRB and RISE10RhL FKBP polypeptides, and the RISE33RhL FRB and RISE33RhL FKBP polypeptides exhibited signaling activity after rapamycin treatment.

[0165] Example 2: Assessment of in vitro activation of STAT5 by CISC2 constructs The signaling activity of the chimeric signaling receptors shown in Figure 4A was examined. InvivoGen HEK-BLUE™ IL2 reporter cells, in which secreted embryonic alkaline phosphatase (SEAP) is released upon production of STAT5, were used. The reporter cells were transfected with the chimeric signaling receptors shown in Figure 4A. After incubation, the reporter cells were exposed to no stimulation (negative control), IL2 (positive control), IL2, or IL2 plus rapamycin. A colorimetric enzyme assay was performed to quantify secreted embryonic alkaline phosphatase, and the results are shown in Figure 4B. Rapamycin induced activation of the IL2 / STAT5 pathway in all constructs containing extracellular FKBP and FRB domains (CISC1a, Chimera 2, Chimera 3, and hsCISC).

[0166] Example 3: Dosage evaluation of in vitro activation of the ST2 pathway by RISE33 constructs The signaling activity of RISE33 constructs was examined. InvivoGen HEK-BLUE™ IL2 reporter cells were used, in which secreted embryonic alkaline phosphatase (SEAP) is released upon production of AP1 and NF-kB. Reporter cells were transfected with RISE33 constructs (human and mouse) shown in Figures 2 and 5. After incubation, reporter cells were exposed to various levels of rapamycin or IL33. A colorimetric enzyme assay was performed to quantify secreted embryonic alkaline phosphatase, and the results are shown in Figure 6A (human) and Figure 6B (mouse). CISC33 was activated by stimuli, and a dose response to the stimuli was observed.

[0167] Example 4: Evaluation of in vitro activation of IL10 by RISE10 constructs The signaling activity of the RISE10 constructs (Figures 2 and 7) was examined. InvivoGen HEK-BLUE™ IL2 reporter cells were used, in which secreted embryonic alkaline phosphatase (SEAP) is released upon production of STAT3 (from IL10 signaling). The reporter cells were transfected with RISE10 constructs containing various levels of IL10, rapamycin, and synthetic linker (G4S) x 3 ("CISC10RaL") or RISE10 constructs containing rapamycin and the IL10 hinge domain ("CISC10RhL"). A colorimetric enzyme assay was performed to quantify secreted embryonic alkaline phosphatase, and the results are shown in Figure 8. CISC10RaL cells were observed to reach a peak plateau at a dose of 0.1 nM, while CISC10RhL cells were observed to reach a peak plateau at a dose of 0.01 nM, which corresponds to a dose of 10 ng / ml of IL10. These results indicate that stimulation with rapamycin activates the IL10 signaling pathway through CISC10 and that at certain low doses, CISC10RhL cells are more sensitive to rapamycin activation than CISC10RaL cells.

[0168] Example 5: In vitro expression of RISE33 constructs and evaluation of associated activation In vitro expression of RISE33 in human CD4+ T cells was examined. Human CD4+ T cells were transfected with a RISE33 construct containing a V5 tag (for flow cytometry). Briefly, human CD4+ T cells were thawed and stimulated with beads (3:1 ratio) (day 0). One day later, 2 × 10 5 The cells were transduced with a lentiviral vector containing the RISE33 construct (day 1). The next day, the cells were supplemented with IL-2 (day 2). The cells were detached from the beads and expanded 24 hours later (day 3). The cells were phenotyped on day 6. The results are shown in Figure 10 and indicate that the RISE33 construct was successfully expressed in T cells.

[0169] Further experiments investigated T cell activation in CD4+ T cells and Jurkat cells transfected with RISE33 constructs (controls were mock-transfected T CD4+ T cells and mock-transfected Jurkat cells). In this experiment, cells were stained for CD69, which is upregulated after IL-33 signaling (Thierry et al., 2014; Polo et al., 2019). As can be seen in Figure 11, T cell activation was more pronounced in the presence of rapamycin in RISE33-transfected cells. Furthermore, an increase in P65-NFκB signaling was observed in cells stimulated with rapamycin (100 nM) for 10 min (1.32% of RISE33-transfected cells vs. 0.49% of mock cells; data not shown). This indicates increased activation of RISE33-transfected T cells in response to rapamycin.

[0170] Other embodiments All features disclosed in this specification may be combined in any combination. Each feature disclosed in this specification may be replaced by alternative features serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is only one example of a generic series of equivalent or similar features.

[0171] From the above description, those skilled in the art can easily grasp the essential features of the present disclosure, and can make various changes and modifications to the present disclosure to adapt it to various usages and conditions without departing from the spirit and scope thereof. Accordingly, other embodiments are within the scope of the claims.

[0172] Equivalent Although several inventive embodiments have been described and illustrated herein, those skilled in the art will readily conceive of various other means and / or structures for performing the functions and / or obtaining one or more of the results and / or advantages described herein. Each such variation and / or modification is deemed to be within the scope of the inventive embodiments described herein. More generally, those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are meant to be exemplary, and that the actual parameters, dimensions, materials, and / or configurations will depend on the particular application in which the teachings of the present invention are used. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific inventive embodiments described herein. Thus, the foregoing embodiments are presented by way of example only, and it will be understood that within the scope of the appended claims and their equivalents, the inventive embodiments may be practiced otherwise than as specifically described and claimed. The inventive embodiments of the present disclosure are directed to each individual feature, system, article, material, kit, and / or method described herein. Furthermore, any combination of two or more of such features, systems, articles, materials, kits, and / or methods, if such features, systems, articles, materials, kits, and / or methods are not mutually inconsistent, is also within the inventive scope of the present disclosure.

[0173] All definitions defined and used herein should be understood to take precedence over dictionary definitions, definitions in documents incorporated by reference, and / or ordinary meanings of the defined terms.

[0174] All references, patents, and patent applications disclosed herein are incorporated by reference with respect to the specific subject matter for which they are cited, and may in some cases include the entire document.

[0175] The indefinite article "a", as used in the specification and claims, unless clearly indicated otherwise, should be understood to mean "at least one". The term "and / or" as used in the present specification and claims should be understood to mean "either or both" of the elements conjoined by the term, i.e., elements that are conjunctive in some cases and disjunctive in other cases. Multiple elements listed with "and / or" should be construed in the same manner, i.e., "one or more" of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the "and / or" clause, whether or not related to the specifically identified elements. Thus, as a non-limiting example, a reference to "A and / or B" when used with open-ended language such as "comprising" may refer in one embodiment to only A (optionally including elements other than B), in another embodiment to only B (optionally including elements other than A), in yet another embodiment to both A and B (optionally including other elements), etc.

[0176] As used herein and in the claims, "or" should be understood to have the same meaning as "and / or" as defined above. For example, when separating items in a list, "or" or "and / or" shall be interpreted as inclusive, i.e., including at least one, but also including more than one number or list element, and optionally including additional items not included in the list. Only terms clearly indicated otherwise, such as "only one of" or "exactly one of," or, when used in the claims, "consisting of," will refer to the inclusion of exactly one number element or list of elements. Typically, the term "or" as used herein will only be interpreted to indicate exclusive alternatives (i.e., "one or the other but not both") when preceded by a term of exclusivity, such as "either," "one of," "only one of," or "exactly one of." "Consisting essentially of," when used in the claims, shall have its ordinary meaning as used in the field of patent law.

[0177] As used in this specification and claims, the phrase "at least one" in reference to a list of one or more elements should be understood to mean at least one element selected from any one or more elements in the list of elements, but not necessarily including at least one and every element specifically listed in the list of elements, and not excluding any combinations of elements in the list of elements. This definition also allows for elements other than those specifically identified in the list of elements to which the phrase "at least one" refers, whether related or unrelated to those elements specifically identified, may optionally be present. Thus, as a non-limiting example, "at least one of A and B" (or, equivalently, "at least one of A or B," or, equivalently, "at least one of A and / or B") can refer in one embodiment to at least one (optionally including more than one) A and no B (and optionally including elements other than B), in another embodiment to at least one (optionally including more than one) B and no A (and optionally including elements other than A), in yet another embodiment to at least one (optionally including more than one) A and at least one (optionally including more than one) B (and optionally including other elements), etc.

[0178] It should also be understood that, unless expressly indicated otherwise, in any method claimed herein that includes two or more steps or actions, the order of the method steps or actions is not necessarily limited to the order of the method steps or actions described.

[0179] In the claims and the above specification, all transitional phrases such as "comprises," "carries," "has," "contains," "carries," "composed," etc., should be understood to be open-ended, i.e., meaning including but not limited to. Only the transitional phrases "consisting of" and "consisting essentially of" are intended to be closed or semi-closed transitional phrases, respectively, as described in the United States Patent Office's Manual of Patent Examining Procedures, Section 2111.03. It should be understood that embodiments described in this document using open-ended transitional phrases (e.g., "comprises") are also contemplated as "consisting of" and "consisting essentially of" the features described by the open-ended transitional phrase in alternative embodiments. For example, if the disclosure describes a "composition comprising A and B," the disclosure also contemplates a "composition consisting of A and B" and a "composition consisting essentially of A and B" as alternative embodiments.

Claims

1. A chimeric signaling receptor for controlling ST2 signaling in a cell, the chimeric signaling receptor comprising a first polypeptide and a second polypeptide, the first polypeptide comprises a first extracellular domain, a first transmembrane domain, and a first membrane proximal signaling domain; the second polypeptide comprises a second extracellular domain, a second transmembrane domain, and a second membrane proximal signaling domain; the first extracellular domain comprises the rapamycin binding domain of FK binding protein 12 (FKBP) or a functional fragment thereof; the second extracellular domain comprises the rapamycin binding domain of FKBP12-rapamycin binding domain of mTOR (FRB) or a functional fragment thereof; (i) the first membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of ST2 and the second membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL1RAP; or (ii) A chimeric signaling receptor, wherein the first membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL1RAP, and the second membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of ST2.

2. A chimeric signaling receptor for controlling IL18R signaling in a cell, the chimeric signaling receptor comprising a first polypeptide and a second polypeptide, the first polypeptide comprises a first extracellular domain, a first transmembrane domain, and a first membrane proximal signaling domain; the second polypeptide comprises a second extracellular domain, a second transmembrane domain, and a second membrane proximal signaling domain; the first extracellular domain comprises the rapamycin binding domain of FK binding protein 12 (FKBP) or a functional fragment thereof; the second extracellular domain comprises the rapamycin binding domain of FKBP12-rapamycin binding domain of mTOR (FRB) or a functional fragment thereof; (i) the first membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL18R1 and the second membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL18RAP; or (ii) a chimeric signaling receptor, wherein the first membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL18RAP, and the second membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL18R1.

3. A chimeric signaling receptor for controlling IL36R signaling in a cell, the chimeric signaling receptor comprising a first polypeptide and a second polypeptide, the first polypeptide comprises a first extracellular domain, a first transmembrane domain, and a first membrane proximal signaling domain; the second polypeptide comprises a second extracellular domain, a second transmembrane domain, and a second membrane proximal signaling domain; the first extracellular domain comprises the rapamycin binding domain of FK binding protein 12 (FKBP) or a functional fragment thereof; the second extracellular domain comprises the rapamycin binding domain of FKBP12-rapamycin binding domain of mTOR (FRB) or a functional fragment thereof; (i) the first membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL36R and the second membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL1RAP; or (ii) a chimeric signaling receptor, wherein the first membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL1RAP, and the second membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL36R.

4. A chimeric signaling receptor for controlling IL10R signaling in a cell, the chimeric signaling receptor comprising a first polypeptide and a second polypeptide, the first polypeptide comprises a first extracellular domain, a first transmembrane domain, and a first membrane proximal signaling domain; the second polypeptide comprises a second extracellular domain, a second transmembrane domain, and a second membrane proximal signaling domain; the first extracellular domain comprises the rapamycin binding domain of FK binding protein 12 (FKBP) or a functional fragment thereof; the second extracellular domain comprises the rapamycin binding domain of FKBP12-rapamycin binding domain of mTOR (FRB) or a functional fragment thereof; (i) the first membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL10R1 and the second membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL10R2; or (ii) A chimeric signaling receptor, wherein the first membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL10R2, and the second membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of IL10R1.

5. A chimeric signaling receptor for controlling LIFR signaling in a cell, the chimeric signaling receptor comprising a first polypeptide and a second polypeptide, the first polypeptide comprises a first extracellular domain, a first transmembrane domain, and a first membrane proximal signaling domain; the second polypeptide comprises a second extracellular domain, a second transmembrane domain, and a second membrane proximal signaling domain; the first extracellular domain comprises a rapamycin binding domain of FKBP or a functional fragment thereof, and the second extracellular domain comprises a rapamycin binding domain of FKBP12-rapamycin binding domain of mTOR (FRB) or a functional fragment thereof; (i) the first membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of gp130 and the second membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of LIFrβ; or (ii) A chimeric signaling receptor, wherein the first membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of LIFrβ, and the second membrane proximal signaling domain comprises an intracellular signaling domain or functional fragment of gp130.

6. 1. A chimeric signaling receptor comprising a first polypeptide and a second polypeptide, the first polypeptide comprises a first extracellular domain, a first transmembrane domain, a first membrane proximal signaling domain, and a first membrane distal signaling domain; The second polypeptide comprises a second extracellular domain, a second transmembrane domain, a second membrane proximal signaling domain, and a second membrane distal signaling domain.

7. the first membrane proximal signaling domain comprises an intracellular signaling domain or a functional fragment of ST2; the second membrane proximal signaling domain comprises an intracellular signaling domain or a functional fragment of IL1RAP; the first membrane distal signaling domain comprises an intracellular signaling domain or a functional fragment of IL2Rγ; The chimeric signaling receptor of claim 6 , wherein the second membrane distal signaling domain comprises an intracellular signaling domain or a functional fragment of IL2Rβ.

8. The chimeric signal transduction receptor of any one of claims 1 to 7, further comprising an extracellular linker.

9. 9. The chimeric signaling receptor of claim 8, wherein the extracellular linker comprises a (G4S)xN peptide linker or an extracellular hinge of IL1RI, IL1RII, IL1RAP, IL2Rβ, IL2Rγ, IL10R1, IL10R2, IL18R1, IL18RAP, ST2, IL36R, LIFrβ, or gp130.

10. 1. A chimeric signaling receptor comprising a first polypeptide and a second polypeptide, wherein the first polypeptide and the second polypeptide each comprise a sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity to a sequence selected from SEQ ID NOs: 1-19.

11. The chimeric signaling receptor of claim 10, wherein the first polypeptide and the second polypeptide are each identical to a sequence selected from SEQ ID NOs: 1-19.

12. A nucleic acid encoding the first or second polypeptide of a chimeric signaling receptor according to any one of claims 1 to 11.

13. The nucleic acid of claim 12 , wherein the nucleic acid encodes the first polypeptide and the second polypeptide.

14. 14. The nucleic acid of claim 12 or 13, further comprising a promoter operably linked to a coding sequence encoding the first polypeptide and / or the second polypeptide.

15. The nucleic acid of claim 14, wherein the promoter is a constitutive promoter.

16. The nucleic acid of claim 15, wherein the constitutive promoter is EF-1α, a PGK promoter, or an MND promoter.

17. The nucleic acid of claim 16, wherein the promoter is an MND promoter.

18. The nucleic acid according to any one of claims 15 to 17, wherein the promoter is an inducible promoter.

19. 19. The nucleic acid of claim 18, wherein the inducible promoter is inducible by a drug or steroid.

20. A vector comprising the nucleic acid according to any one of claims 12 to 19.

21. The vector of claim 20 , wherein the vector is a viral vector.

22. 22. The vector of claim 20 or 21, wherein the vector is an adenovirus-associated virus (AAV) vector.

23. 23. The vector of claim 22, wherein the AAV vector is derived from AAV of serotype AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, or AAV11.

24. The vector of claim 21 , wherein the viral vector is a lentiviral vector.

25. The vector of claim 20 , wherein the vector is a plasmid.

26. The vector of claim 20 , wherein the vector is a bacterial artificial chromosome.

27. The vector of claim 20 , wherein the vector is a human artificial chromosome.

28. A lipid nanoparticle comprising the nucleic acid according to any one of claims 12 to 19 or the vector according to any one of claims 20 to 27.

29. A cell comprising the chimeric signal transduction receptor of any one of claims 1 to 7 or the nucleic acid of any one of claims 12 to 19.

30. 30. The cell of claim 29, wherein the cell is a stem cell or a T cell.

31. 31. The cell of claim 29 or 30, wherein the cell is a CD3+, CD4+, or CD8+ T cell.

32. The cell according to any one of claims 29 to 31, wherein the cell is a Treg cell.

33. The cell of any one of claims 29 to 32, wherein the cell is a FoxP3+ Treg cell.

34. 34. The cell of any one of claims 29 to 33, wherein the cell is CTLA-4+, LAG-3+, CD25+, CD39+, CD27+, CD70+, GITR+, Neuropilin-1+, Galectin-1+, and / or IL-2Rα+.

35. The cell of any one of claims 29 to 34, wherein the cell promotes proliferation of Tregs.

36. The cell of any one of claims 29 to 34, wherein the cell has an ST2 phenotype.

37. The cell of any one of claims 29 to 34, wherein the cell has a Tr1 phenotype.

38. A pharmaceutical composition comprising the cells of any one of claims 29 to 37 and rapamycin or a rapalog.

39. A method comprising administering to a subject the pharmaceutical composition according to claim 38 or the cell according to any one of claims 29 to 37.

40. 40. The method of claim 39, wherein the subject has or is at risk of developing an inflammatory disease, an autoimmune disease, an allergic disease, or a condition associated with solid organ transplantation.

41. 41. The method of claim 40, wherein the inflammatory disease is selected from pancreatic islet cell transplantation, asthma, hepatitis, traumatic brain injury, primary sclerosing cholangitis, primary biliary cholangitis, polymyositis, stroke, Still's disease, acute respiratory distress syndrome (ARDS), uveitis, inflammatory bowel disease (IBD), ulcerative colitis, graft versus host disease (GvHD), induced tolerance to transplantation, transplant rejection, or sepsis.

42. 41. The method of claim 40, wherein the autoimmune disease is type 1 diabetes, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, rheumatoid arthritis, early onset rheumatoid arthritis, ankylosing spondylitis, immune-mediated abortion, immune-mediated recurrent abortion, dermatomyositis, psoriatic arthritis, Crohn's disease, inflammatory bowel disease (IBD), ulcerative colitis, bullous pemphigoid, pemphigus vulgaris, autoimmune hepatitis, psoriasis, Sjogren's syndrome, or celiac disease.

43. 41. The method of claim 40, wherein the allergic disease is allergic asthma, steroid-resistant asthma, atopic dermatitis, celiac disease, pollen allergy, food allergy, drug hypersensitivity, or contact dermatitis.

44. 41. The method of claim 40, wherein the condition associated with a solid organ transplant is graft-versus-host disease.

45. The method of any one of claims 39 to 44, wherein the cells are autologous to the subject.

46. The method of any one of claims 39 to 44, wherein the cells are allogeneic cells.

47. A method for producing a modified cell, comprising introducing into a cell a nucleic acid according to any one of claims 12 to 19.